1 **Article type:** Review Prediction of oncogene mutation status in non-small cell lung cancer: A 2 systematic review and meta-analysis with a special focus on artificial-3 4 intelligence-based methods 5 Almudena Fuster-Matanzo<sup>†1</sup>, Alfonso Picó Peris<sup>†1</sup>, Fuensanta Bellvís Bataller<sup>1</sup>, Ana 6 Jimenez-Pastor<sup>1</sup>, Glen J. Weiss<sup>2</sup>, Luis Martí-Bonmatí<sup>3,4</sup>, Antonio Lázaro Sánchez<sup>5</sup>. 7 Giuseppe L. Banna<sup>6</sup>, Alfredo Addeo<sup>7</sup>, Ángel Alberich-Bayarri<sup>1</sup> 8 9 10 <sup>1</sup>Quantitative Imaging Biomarkers in Medicine (Quibim), 46021 Valencia, Spain 11 <sup>2</sup>Quantitative Imaging Biomarkers in Medicine, Quibim, Boston, MA, USA, Boston, 12 MA <sup>3</sup>Grupo de Investigación Biomédica en Imagen, Instituto de Investigación Sanitaria La 13 14 Fe, Avenida Fernando Abril Martorell, 106 Torre A planta 7, 46026, Valencia, Spain. 15 <sup>4</sup>Área Clínica de Imagen Médica, Área Clínica de Imagen Médica, Hospital Universitari 16 i Politècnic La Fe, Avinguda Fernando Abril Martorell, 106 Torre E planta 0, 46026, 17 València, Spain. 5 18 <sup>6</sup>Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, 19 20 PO6 3LY, UK; Faculty of Science and Health, School of Pharmacy and Biomedical 21 Sciences, University of Portsmouth, Portsmouth, PO1 2UP, UK 22 <sup>7</sup>University Hospital Geneva, Geneva, Switzerland. <sup>†</sup>These authors contributed equally to this work. 23 24

25 Correspondence:

26 Almudena Fuster-Matanzo

- 27 Quantitative Imaging Biomarkers in Medicine (Quibim),
- 28 EDIFICIO EUROPA, Av. d'Aragó, 30, Planta 13
- 29 46021 Valencia, Spain
- 30 Mail: almudenafuster@quibim.com
- 31 Tel: +34 652124031

## **ABSTRACT**

33

34

40

## Background

- 35 In non-small cell lung cancer (NSCLC), alternative strategies to determine patient
- 36 oncogene mutation status are essential to overcome some of the drawbacks associated
- 37 with current methods. We aimed to review the use of radiomics alone or in combination
- with clinical data and to evaluate the performance of artificial intelligence (AI)-based
- 39 models on the prediction of oncogene mutation status.

#### Methods

- 41 A PRISMA-compliant literature review was conducted. The Medline (via Pubmed),
- 42 Embase, and Cochrane Library databases were searched for studies published through
- 43 June 30, 2023 predicting oncogene mutation status in patients with NSCLC using
- radiomics. Independent meta-analyses evaluating the performance of AI-based models
- 45 developed with radiomics features or with a combination of radiomics features plus
- 46 clinical data for the prediction of different oncogenic driver mutations were performed.
- 47 A meta-regression to analyze the influence of methodological/clinical factors was also
- 48 conducted.

49

## Results

- Out of the 615 studies identified, 89 evaluating models for the prediction of epidermal
- 51 growth factor-1 (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma
- 52 virus (KRAS) mutations were included in the systematic review. A total of 38 met the
- 53 inclusion criteria for the meta-analyses. The AI algorithms' sensitivity/false positive rate
- 54 (FPR) in predicting EGFR, ALK, and KRAS mutations using radiomics-based models
- 55 was 0.753 (95% CI 0.721–0.783)/0.346 (95% CI 0.305–0.390), 0.754 (95% CI 0.639–
- 56 0.841)/ 0.225 (95% CI 0.163–0.302), and 0.744 (95% CI 0.605–0.846)/0.376 (95% CI
- 57 0.274–0.491), respectively. A meta-analysis of combined models was only possible for
- 58 EGFR mutation, revealing a sensitivity/FPR of 0.800 (95% CI 0.767–0.830)/0.335
- 59 (95% CI 0.279–0.396). No statistically significant results were obtained in the meta-
- 60 regression.

61

#### Conclusions

- 62 Radiomics-based models may represent valuable non-invasive tools for the
- 63 determination of oncogene mutation status in NSCLC. Further investigation is required
- to analyze whether clinical data might boost their performance.
- 65 **Keywords:** radiomics, artificial intelligence, medical imaging, oncogene mutation
- status, non-small cell lung cancer.

#### INTRODUCTION

68

69

70

71

72

73

74

75

76

77

78

79

80

8182

83

84

85

86

87

88

89

90

91

92

93

94

95

96 97

98

99

100

Lung cancer represents the most often diagnosed cancer in both women and men worldwide, ranking first and third, respectively, and remaining the leading cause of cancer death<sup>1</sup>. Non-small cell lung cancer (NSCLC), the most frequent histological subtype, accounts for 80%-85% of cases, being adenocarcinoma the most common subtype (40%-50% of cases). Adenocarcinoma can be further subdivided into distinct molecular subtypes<sup>2</sup>. Indeed, molecular subtyping has become highly relevant in the disease context, as genotype-driven therapy ("targeted therapy") is nowadays the standard of care for a significant subgroup of patients with advanced and metastatic NSCLC<sup>3</sup>. However, traditional methods for determining the molecular genotype, as well as the possible emergence of drug resistance mutations during patient's follow-up, entail invasive biopsies and genetic sequence testing, procedures with multiple number of associated drawbacks including high costs, sampling bias, lack of enough sample, turnaround time, and medical complications<sup>4-6</sup>. Importantly, the overall accessibility of molecular diagnostics and liquid biopsy may be limited for many patients<sup>7</sup>, highlighting the need to investigate complementary methods to characterize the oncogene mutation status of lesions. Radiological imaging represents a potent non-invasive tool for lung cancer, from the screening, diagnosis and staging of the disease to the management, therapeutic planification and follow-up of both early- and advanced-stage cases<sup>8</sup>. Specifically, computed tomography (CT) remains the standard of care for lung cancer visualization, providing excellent morphological and textural information. In recent years, radiomics, the process of extracting and analyzing quantitative features from medical images to investigate potential connections with biology and clinical outcomes, has gained increasing attention for its applicability in several oncological diseases including lung cancer<sup>8</sup>. The application of artificial intelligence (AI) to imaging analyses has enabled important clinical needs to be met. This includes the prognostication of outcomes or the prediction of response to treatment, disease progression, or the mutational and molecular profiling of tumors<sup>9</sup>. In particular, the use of radiomics coupled with AI methods has demonstrated to be a promising non-invasive alternative tool for the prediction of oncogene mutation status in NSCLC<sup>8</sup>. In this systematic review and meta-analysis we aimed to: 1) review the available scientific evidence on the use of imaging-based models and radiomics for the prediction

101 of the main targetable oncogenic driver alterations in NSCLC, including epidermal 102 growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat 103 sarcoma virus (KRAS); 2) analyze the overall performance of specifically, AI-based 104 methods, for the prediction of oncogene mutation status; 3) evaluate whether the 105 inclusion of clinical variables in the models improve their performance; 4) evaluate the 106 impact of the available evidence from a clinical perspective. 107 MATERIAL AND METHODS 108 This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines<sup>10</sup>. The review was 109 registered on PROSPERO before initiation (registration no. CRD42022349809). 110 111 **Search strategy** 112 A systematic search for eligible publications published through 30 June 2023 was per-113 formed in Medline (via Pubmed), Cochrane Library and EMBASE databases using the 114 keywords "Radiomics", "NSCLC" and "Mutational status". Further details on the 115 search terms used in each database are provided in Supplementary Table S1. There 116 were no limitations on the publishing year, participant age, or nationality. The search 117 was exclusively limited to English-language publications. 118 **Study selection** 119 Literature search and study selection were independently performed by two reviewers 120 (A.F.M. and A.L.S.). To find relevant publications, they reviewed the titles and 121 abstracts. Studies that satisfied the inclusion criteria were then manually assessed for 122 eligibility by full-text screening. Covidence systematic review software (Veritas Health 123 Innovation, Melbourne, Australia. Available at www.covidence.org) was used as a 124 screening and data extraction tool. 125 Inclusion criteria 126 Papers were included in the qualitative synthesis (systematic review) if meeting the 127 following inclusion criteria based on Patient, Index test, Comparator, Reference test, 128 Diagnosis of reference (PIRD) questions: 1) being focused on the ability of radiomics to 129 predict oncogene mutation status in NSCLC; 2) radiomics features were extracted from 130 CT or from F-18 fluoro-deoxy-glucose (FDG)/CT scans; 3) a full text was available; 4)

131

were written in English.

132 Exclusion criteria 133 Papers describing studies conducted using MRI scans (not the standard of care for 134 NSCLC patients) or performed in phantom or animal models, or published as case 135 reports, editorials, reviews, poster presentations, letters, editorials, or meeting abstracts 136 were excluded. Papers not on the field of interest were also excluded. 137 For the quantitative synthesis (meta-analysis), the following additional exclusion 138 criteria were applied: 1) oncogene mutation status was not the primary objective of the 139 paper; 2) were focused on specific mutation subtypes; 3) did not apply AI-based 140 methodologies; 4) developed simultaneous detection models or discriminant models; 5) 141 sensitivity or specificity metrics were not available and could not be calculated; 6) were 142 not comparable with the other articles included (model was developed based on intra-143 and extra-tumor derived radiomics features); 7) only included models developed with a 144 combination of quantitative features extracted from PET/CT or from PET images 145 (strictly adhering to a clinical perspective, PET scanning equipment is not always 146 available and CT remains the standard of care for NSCLC patients); 8) did not reach a 147 sufficient quality score according to the quality assessment (described below). 148 Quality assessment 149 The methodological quality of each study for its possible inclusion in the quantitative 150 assessment was evaluated by using the Checklist for Artificial Intelligence in Medical 151 Imaging (CLAIM)<sup>11</sup>. Classification, image reconstruction, text analysis, and workflow 152 optimization are some of the applications of AI in medical imaging that are addressed by CLAIM, which is modeled after the Standards for Reporting of Diagnostic Accuracy 153 Studies (STARD) guideline 12-15. CLAIM checklist consists of 42 items divided into the 154 155 conventional sections included in peer-reviewed scientific articles: title or abstract (1 156 item), abstract (1 item), introduction (2 items), methods (28 items subdivided into study 157 design [2 items], data [7 items], ground truth [5 items], data partitions [3 items], model [ 158 3 items], training [3 items] and evaluation [5 items]), results (5 items subdivided into 159 data [2 items] and model performance [3 items]), discussion (2 items) and other 160 information (3 items). The CLAIM guideline offers a roadmap for writers and reviewers with the intention of fostering clear, open, and verifiable scientific discourse on the use 161 of AI in medical imaging<sup>11</sup>. 162

For our quality assessment, a score was calculated for each paper ([total score, 42 - number of "not applicable" fields in each case]). A cut-off value of at least half of the total score after removing the "not applicable" items was established for the inclusion in the quantitative analysis. Therefore, this cut-off value varied for each study depending on the number of items that were applicable from among the 42 total items included in the CLAIM checklist (e.g., a cut-off value of 19 was established for those studies in which only 38 items of the checklist were applicable). **See Supplementary Table S2**. The assessment of the rigor, quality, and generalizability of the work of all enrolled studies was performed by three reviewers (A.J.P., F.B.B. and A.P.P.).

## Data extraction

Data extracted included the following: (1) study details: first author, publication year, research questions, study design; (2) patient details: the source of data acquisition (single-center/multicenter), sample size, smoking history, age, sex, TNM staging, treatment status (naïve or any treatment received prior image acquisition), histological subtype; (3) imaging details: imaging modality, plain or contrast CT; (4) oncogene mutation status-related information: type of mutation, specific subtype of mutation (if available), sequencing method; sequencing kit (5) radiomics details: segmentation software, type of segmentation (manual, automatic, or semi-automatic), radiomics feature extraction software, number of imaging features extracted, number and name of radiomics features included in final models, features selection methods, type of models constructed (machine learning [ML], deep learning [DL], classical statistical model), final classifier used in machine learning models, clinical variables included in the models (if applicable), and models performance. Two independent reviewers (A.F.M. and A.L.S.) completed the initial screening and extracted data from all included studies.

#### Data analysis

For studies including models based on features extracted from different imaging modalities, only those based on CT scans were included in the quantitative analysis. A bivariate analysis of sensitivity and specificity as proposed by Reitsma et al. was chosen to perform the meta-analyses. This method has the distinct advantage of preserving the two-dimensional nature of the underlying data. It can also produce summary estimates of sensitivity and specificity (false positive rate [FPR, 1-specificity]), recognizing any possible correlation between these two measures. The

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

method uses a random effect approach in which the values of the sensitivity and FPR estimates are obtained with restricted maximum likelihood. As a complement to the bivariate approach, the summary receiver operating characteristic (sROC) was calculated by converting each pair of sensitivity and specificity into a single measure of accuracy, the diagnostic odds ratio (DOR). The analyses were carried out by reproducing the confusion matrices of each model presented in the studies, the number of cases and the prevalence of oncogene mutant positive cases. All calculations were performed on the basis of validation cohorts for studies applying a training/validation split method, or on the basis of the total sample when cross-validation was the validation strategy. To ensure homogeneity, calculations were conducted based on internal validation cohort data when external validation was also performed (minority of the cases). Finally, a meta-regression analysis was performed to measure the possible influence of the following predictors: (1) average age of the cases, (2) manual segmentation vs semiautomatic segmentation vs both procedures (no studies including automatic segmentation approaches met the inclusion criteria for the quantitative analysis), (3) whether the model included only radiomics features or was combined with clinical variables, and (4) whether the model was classified as ML or DL. The heterogeneity in the description of the clinical variables included in the models prevented the inclusion of additional predictors of greatest clinical interest. Only the best model from each study according to its DOR was selected. When the mean/median age was not available due to the heterogeneity among studies when presenting descriptive results, it was inferred from the information obtained. Thus, mean and median values were indistinctly considered; when both values were provided, an average of both was calculated. If mean values were absent, median values were considered and viceversa. If both values were absent from the validation cohort, mean/median age from the total cohort was considered. When this information was not available either, the study was not included in the meta-regression. All the analyses were performed using R Statistical Software v4.2.2 and the packages mada and tidyverse.

#### RESULTS

225

233

- In total 615 articles were obtained according to the search strategy (Figure 1). After de-
- duplication, 397 studies were obtained and screened. According to the inclusion and
- 228 exclusion criteria, 89 studies were included in the qualitative analysis (systematic
- 229 review), all of them developing models for the prediction of EGFR, ALK, and/or
- 230 KRAS. Out of those, 38 were found eligible for the quantitative part of the study (meta-
- analyses). As detailed in **Supplementary Table S2**, all papers passed this quality check
- and were therefore included.

## **Qualitative analysis (systematic review)**

- 234 *Methodological characteristics of the studies*
- 235 The methodological characteristics of the studies are summarized in **Table 1**. Most of
- the studies (n = 69/89) applied exclusively ML algorithms, while this methodology was
- also used to build comparator models in 10 articles in which DL techniques were the
- 238 main methodological approach followed. Only three studies exclusively applied DL
- 239 algorithms, while classical statistical models were used in seven publications. Among
- 240 the 79 articles applying ML techniques, the most common classifier used was logistic
- regression (n = 38), followed by support vector machine (n = 35) and by random forest
- (n = 29). In terms of partitioning strategy, training-validation split was the most frequent
- 243 technique (n = 71). External validation was only performed in a small set of studies
- (n = 9). Regarding imaging techniques, CT was the most frequently used modality
- 245 (n = 61), followed by PET/CT (n = 22) and by PET alone (n = 4). Additionally, in one
- 246 study<sup>17</sup> PET/CT scans and contrast-enhanced CT images independently acquired were
- 247 collected, while in another study<sup>18</sup>, PET/CT, CT, and contrast-enhanced diagnostic
- 248 quality (CTD) images were used. Of the 61 studies conducted with CT scans, 39
- 249 included non-contrast-enhanced images, 18 contrast-enhanced images, in two contrast-
- 250 related information was not specified and in two both contrast- and non-contrast-
- enhanced scans were included. Regarding tumor segmentation, a manual approach was
- 252 followed in 48 studies, and automatic and semi-automatic segmentations were applied
- 253 in two and 31 studies, respectively; three studies applied both methodologies (for
- verification or a different approach according to the imaging modality used) and five
- studies did not specify the method utilized for tumor segmentation.
- 256 Clinical characteristics of the studies

258

259

260

261

262263

264

265

266

267

268

269270

271

272

273

274

275

276

277278

279

280

281

282

283

284285

286287

288

The 89 studies evaluated in the qualitative synthesis included a total of 32,084 patients with NSCLC. Although most of the studies included >200 patients, in 42 publications, the sample size did not reach this figure and in 11 studies sample size was even lower than 100. All studies were retrospective and mostly unicentric (n = 72); the number of participant centers was not specified in one study<sup>19</sup>. In general, basic clinical and demographic information collected included sex, age, smoking status, TNM stage, histology, and treatment status at the moment of image acquisition, although this information was not available in 13, 9, 22, 34, 22 and 24 studies out of the 89 assessed, respectively. The clinical characteristics of the patients included in the 89 studies are depicted in Table 2. The median [range]/ mean ± standard deviation (SD) age of patients was 61.78 [59–64.17] years and  $61.71 \pm 3.64$  years, respectively. In terms of sex, the total population was balanced, with 13,574 females and 14,066 males. The smoking history was available for 23,200 patients, and many were non-smokers (n = 12,813); while smoking history was unknown for 1,146 patients. Out of the 55 studies detailing information about the TNM stage, the majority of them (n = 40)included information about the four stages (I-IV), either provided per group or grouped in stages I-II and stages III-IV. Among the 15 studies that did not include patients of all stages, two studies included only early stage patients (stages I and II)<sup>20, 21</sup>, two included patients stage II-IV<sup>22, 23</sup>, six included only patients of stages III and IV<sup>24-29</sup> (three of them with a majority of stage IV patients<sup>24, 27, 29</sup>), and five included patients of stages I-III without including the most advanced stage 19, 30-33. A total of 65 studies included patients with adenocarcinoma: 43 exclusively including this histology subtype and 22 including other NSCLC histology types as well. Finally, in most of the cases (n = 65), images were acquired before patients received any treatment, with two studies also including post-treatment images<sup>34, 35</sup>. In 24 studies, no information on treatment was detailed, although in some of them image acquisition before surgery<sup>31, 36-41</sup>, before polymerase chain reaction (PCR)<sup>42</sup>, or before pathological diagnosis<sup>43</sup> was detailed as an inclusion criterion. In five studies 19, 44-47, authors specify that patients had not received radiotherapy or chemotherapy, but no information on targeted therapy was provided. Finally, only one study<sup>48</sup> out of the 89 included in the systematic review, which did not meet the inclusion criteria to be considered for the meta-analysis, included patients who had received treatment with tyrosine kinase inhibitors (TKIs).

**Quantitative analysis (meta-analysis)** 

290 A total of 38 studies met the inclusion criteria for the quantitative assessment 291 (n = 17,066 patients). Three main different meta-analyses including radiomics-based 292 models were conducted: 1) a meta-analysis including studies focused on the detection of EGFR  $(n = 34 \text{ studies})^{17, 25-28, 32, 33, 36, 38, 39, 46, 49-71}$ ; 2) a meta-analysis including studies 293 focused on the detection of ALK  $(n = 3 \text{ studies})^{72-74}$ ; 3) a meta-analysis including 294 studies focused on the detection of KRAS  $(n = 4 \text{ studies})^{47, 50, 54, 62}$ . In three studies, 295 authors developed models for the detection of both EGFR and KRAS<sup>50, 54, 62</sup>. 296 297 Furthermore, a separate meta-analysis was conducted for combined models (radiomics 298 features + clinical variables) for the prediction of EGFR (not enough studies for ALK or 299 KRAS mutations). Studies included in all the meta-analyses conducted are summarized 300 in Supplementary Table S3. Details on the radiomics features included in the EGFR, 301 ALK, and KRAS models are summarized in Supplementary Table S4. 302 Supplementary Table S5 and Supplementary Table S6, respectively. In terms of 303 radiomics variables, models grouped different combinations of first order, shape, gray 304 level co-occurrence matrix (GLCM), gray level size zone matrix (GLSZM), gray level 305 run length matrix (GLRLM), neighboring gray tone difference matrix (NGTDM), and 306 gray level dependence matrix (GLDM) features. Clinical data included sex, smoking 307 history, and/or histological type in the majority of studies.

**EGFR** 

308

309

310

311312

313

314

315

316317

318319

320

289

Results of the meta-analysis focused on models built with radiomics features are summarized in **Figure 2**. Note that this meta-analysis also included a study<sup>50</sup> in which predictions were based on features extracted by a multi-channel and multi-task deep learning model with the ability to simultaneously detect EGFR and KRAS oncogene mutations; and consequently, did not include radiomics features (only single-task results for the independent prediction of EGFR and KRAS were considered for the quantitative analysis). A hierarchical sROC curve was plotted for the included 24 studies <sup>17, 25, 27, 32, 36, 39, 46, 49-51, 54, 55, 57-60, 62, 64-66, 68-71</sup> that evaluate the performance of AI algorithms in predicting EGFR mutation status in NSCLC (**Supplementary Figure S1**). Eight studies assessed more than one model<sup>32, 36, 39, 50, 59, 60, 65, 70</sup>. As observed, radiomics-based models exhibited high diagnostic performance in predicting EGFR mutation status with an overall AUC of 0.766. The AI algorithms' sensitivity in determining the EGFR mutation

321 status varied from 0.362 to 0.948, resulting in an estimate of 0.753 (95% CI 0.721-322 0.783). The FPR of these algorithms ranged from 0.022 to 0.761, with a estimate of 323 0.346 (95% CI 0.305–0.390). Detecting a positive case for EGFR mutation was almost 324 six times more likely than not detecting it (DOR = 5.70 [95% CI 4.74-6.81]). 325 The effect of adding clinical variables to radiomics models or to models including both radiomics and deep features<sup>65</sup> (models including clinical data and radiomic or deep 326 327 features referred in this work as combined models) in the prediction of EGFR mutation was also analyzed. This meta-analysis included 23 studies<sup>25, 26, 28, 32, 33, 38, 39, 46, 51-53, 56-58,</sup> 328 61-69, of which four of them developed more than one model<sup>32, 39, 56, 67</sup>. Results are 329 330 depicted in Figure 3 and sROC curve in Supplementary Figure S1. Overall, the 331 performance of combined models slightly improved compared to radiomics models, 332 with an AUC of 0.811 and a sensitivity of 0.800 (95% CI 0.767-0.830; model's 333 sensitivity ranging from 0.523 to 0.944). The FPR resulted similar with a value of 0.335 334 (95% CI 0.279–0.396; model's FPR ranging from 0.167 to 0.760.). Detecting a positive 335 case for EGFR mutation with combined models was more than eight times more likely 336 than not detecting it (DOR = 8.35 [95% CI 6.77-10.20]). ALK337 The meta-analysis focused on radiomics-based models included three studies<sup>72-74</sup>, one of 338 339 which developed two different models, one based on pre-contrast images and another 340 one on post-contrast images<sup>73</sup>. An overall AUC of 0.831 was obtained for the prediction 341 of ALK aberration, with a sensitivity ranging from 0.682 to 0.825, resulting in an 342 estimate of 0.754 (95% CI 0.639-0.841). The FPR of these algorithms ranged from 343 0.167 to 0.277, with an estimate of 0.225 (95% CI 0.163-0.302). Detecting a positive 344 case for ALK aberration was 11 times more likely than not detecting it (DOR = 5.70 345 [95% CI 5.83–19.10]) (Figure 4 and Supplementary Figure S2). Given the lack of enough studies developing combined models, a meta-analysis to assess the effects of 346 347 adding clinical variables in the prediction of ALK aberration was not possible. The only study<sup>74</sup> that developed a model including age, sex, smoking history, smoking index, 348 349 clinical stage, distal metastasis and pathological invasiveness of the tumor in 350 combination with conventional CT features and different first order, GLCM, GLSZM, 351 and GLRL radiomics features demonstrated increased performance in predicting ALK 352 aberration of the combined model vs the radiomics-based model, but only in the 353 primary cohort (AUC, 0.83-0.88, p=0.01), not in the testing cohort (AUC, 0.80-0.88, 354 p = 0.29). 355 KRAS 356 Four studies met the inclusion criteria for the meta-analysis assessing models for KRAS mutation prediction<sup>47, 50, 54, 62</sup>, among which, three of them also developed models for 357 EGFR mutation prediction<sup>50, 54, 62</sup>. KRAS/EGFR models were independently built 358 359 except in one study, in which a multi-channel multi-task DL model for the prediction of both KRAS and EGFR mutations was developed<sup>50</sup>. However, and according to the 360 361 inclusion criteria, only single-task metrics were considered for the quantitative analysis 362 despite the multi-channel version displayed the highest performance for the simultaneous detection of both oncogenic driver mutations. Results of the meta-analysis 363 evaluating radiomics-based models are shown in Figure 4 and Supplementary Figure 364 365 **S3.** KRAS mutation was predicted with an overall AUC of 0.732 and a sensitivity of 366 0.744 (95% CI 0.605–0.846; model's sensitivity ranging from 0.641 to 0.875. The FPR 367 was 0.376 (95% CI 0.274–0.491; model's FPR ranging from 0.259 to 0.468). Detecting 368 a positive case for KRAS mutation with radiomics-based models was more than five times more likely than not detecting it (DOR = 8.35 [95% CI 1.98–11.70]). Like ALK, 369 370 the lack of enough KRAS studies made it impossible to perform a meta-analysis analyzing combined models. Only Ríos Velázquez et al.<sup>62</sup> built a model including age, 371 372 sex, smoking status, race, and clinical stage together with radiomics features that 373 performed similar to the radiomics model (AUC = 0.69 [95% CI: 0.63-0.75] vs 374 AUC = 0.63 [95% CI: 0.57–0.69]) and worse than a model developed only with clinical 375 data AUC = 0.75 [95% CI: 0.69–0.80]. 376 Meta-regression and subgroup analysis 377 The possible effects of different predictors on the predictive performance of the models 378 was evaluated for EGFR mutation (not enough studies were available for ALK or 379 KRAS mutations). Neither age, nor the use of contrast, nor the type of segmentation 380 (manual/semi-automatic/automatic), nor the model (radiomics/combined), nor the AI

methodology (machine learning/deep learning), yielded statistically significant results

(Supplementary Table S7).

381

384

385

386

387388

389

390391

392

393

394395

396

397

398

399

400

401

402

403

404 405

406

407

408

409

410

411

412

413

414

# **DISCUSSION** At present, molecular testing performed on biopsied tissue remains the gold standard for diagnosis and genotyping in advanced NSCLC<sup>75, 76</sup>. However, given the associated limitations and inconveniences, such as the lack of enough tissue for successful testing<sup>77, 78</sup>, or the long turnaround times<sup>76</sup>, there is a need to validate and incorporate new procedures into routine clinical practice. In recent years, liquid biopsy has emerged as a promising alternative in NSCLC, especially in clinical scenarios<sup>78</sup>. Likewise, radiomics have shown encouraging results in prognosis and prediction in this setting<sup>79</sup>. In general, both methodologies possess great potential, since they are both simple, straightforward to do, and repeatable at patient follow-up visits, which makes it possible to gather important data about the type of tumor, its aggressiveness, its progression, and its response to therapy<sup>80</sup>. Radiomics has the additional advantage of only requiring medical images and capturing patient-level and tissue-level heterogeneity, such as CT scans in lung cancer, that are usually acquired as part of the patient's standard journey, representing an affordable methodology both in terms of resources and costs. It is important that new techniques are properly validated to facilitate their standardization, prior to incorporation into the routine clinical workflow. To our knowledge, this is the first systematic review and meta-analysis that analyzes the performance and applicability of different imaging-based models for the prediction of three of the most common oncogene mutations—EGFR, ALK and KRAS—in NSCLC from a clinical perspective and with a special focus on AI methodologies. So far, results were only available for EGFR studies and did not take clinical aspects into account<sup>81</sup>. Thus, the results of our different meta-analyses demonstrate that AI-based models developed with CT-derived radiomics features showed good performance in predicting EGFR, ALK, and KRAS mutations with a sensitivity of 0.753 [95% CI (0.721–0.783)], 0.754 [95% CI (0.639–0.841)] and 0.744 [95% CI (0.605–0.846)], respectively. Whether the inclusion of clinical variables increase models' performance cannot be concluded from our results, although we believe that increasing the number of studies would probably confirm the trends observed in our quantitative analysis of EGFR mutation.

status determination. We especially focused on CT-based models, aiming to obtain

Our outcomes point to radiomics as a candidate screening tool for oncogene mutation

416 417

418

419

420

421422

423

424

425

426

427

428

429

430

431 432

433

434

435

436

437438

439

440

441

442

443

444

445

446

447

448

conclusions as applicable as possible to the standard clinical workflow since CT remains the most utilized imaging tool in NSCLC<sup>82</sup>. From our work, we conclude that in addition to additional validation of our findings that future studies should be conducted that consider the following important aspects. Firstly, a minimum sample size should be guaranteed to ensure the reliability of the results obtained with AI-based models<sup>83, 84</sup>. In both our systematic review and meta-analyses, more than half of the studies were conducted in >200 patients (n = 46/89 and n = 23/38 [n = 20/34 for EGFR, n = 2/3 for ALK and n = 3/4 for KRAS]), but still a sizable number had small sample sizes, which definitely limited the relevance of their conclusions. Multicentric designs would be also desirable to get more solid conclusions, an approach that few studies followed (n = 16/89 in the systematic review and n = 10/39 in the meta-analysis [n = 10/34 for EGFR, n = 0/3 for ALK and n = 3/4 for KRAS]). Secondly, including independent cohorts for external validations would reinforce the results, leading to more robust and reproducible models. Out of the 89 studies included in the qualitative analysis, only 9 used external cohorts for validation 43, 46, 60, 63, 67, 68, 85-87, of which five were included in the EGFR meta-analysis 46, 60, 63, 67, 68. Finally, it is important that patient populations reflect clinical practice. Thus, considering the potential applicability of the models for diagnostic purposes, studies should be conducted in treatment naïve populations to avoid possible therapy-related confounding effects, an inclusion criterion mostly applied in the studies evaluated in this work, but still missing in some of them. Additionally, studies should be carried out preferably in stage III-IV NSCLC patients (especially in those at stage IV, for whom clinical guidelines recommend molecular testing<sup>75, 76</sup>). As demonstrated in this work, most of the studies published so far do not provide information on TNM stage or include patients from all stages. Despite the heterogeneity of the studies evaluated, we believe that the evidence provided is enough as to demonstrate the potential of radiomics in oncogene mutation status determination. Thus, AI-based models using radiomics extracted from CT scans could be effective noninvasive screening tools to detect targetable driver mutations in NSCLC with good sensitivity and moderate specificity. These tools would not be intended to replace gold standard techniques, such as PCR or next-generation sequencing, but to allow for the potential earlier identification of ideal candidates to be genetically tested, saving time, costs, and samples. Consequently, a high sensitivity would ensure the identification of oncogene mutation positive patients for whom laboratory-based testing would be subsequently confirmed.

450

451

452

453

454

455

456 457

458

459 460

461

462463

464

465

466

467

468

469

470

471

472

473474

475

476

477

478

479

480

481

When the influence of different factors on the prediction of EGFR mutation was evaluated, no statistically significant results were obtained, probably due to the limited number of studies included and the presence of missing data. However, some of those factors might play an essential role and should be considered when developing accurate models to be potentially implemented into clinical practice. Indeed, some of the studies included in our qualitative analysis analyzed the impact of different methodological aspects on the performance of the models. For example, Huang et al.<sup>35</sup> demonstrated that interobserver variability in tumor segmentation affects the use of radiomics to predict oncogene mutation status, which suggests that automatic or semi-automatic models might be more suitable. In the study by Shiri et al.<sup>88</sup>, the application to radiomics features of ComBat harmonization improved the performance of the models toward more successful prediction of EGFR and KRAS mutations. Likewise, other authors have pointed to the impact of the experimental settings on the robustness of radiomics features<sup>89</sup>, or the influence of CT slice thickness on the predictive performance of radiomics-based models<sup>31</sup>. It is also worth mentioning the relevance of using a particular AI methodology. Although we found no differences in the EGFR mutation predictive performance between ML and DL methods, most likely due to the limited number of available DL-based studies, the latter might offer some advantages over the former. Thus, while in radiomics analysis a process of lesion segmentation and subsequent feature extraction is required, which introduces certain degree of variability and can be a high time-consuming task, DL models only required a bounding box of the lesion, greatly reducing this effect. On the other hand, DL models, and in particular endto-end convolutional neural network (CNN) models, such those developed in most of the DL studies included in our work<sup>37, 42, 43, 50, 58, 68, 85, 86, 90, 91</sup>, are generally more complex in terms of the number of parameters, allowing to solve more complicated problems than traditional ML models. Considering available evidence, it seems reasonable to think that methodologic approaches should be carefully revised when validation studies are designed and conducted. Our study has also some limitations, mainly derived from the limitations of the publications included. Thus, it is based on retrospective studies displaying great heterogeneity in terms of methodology and patient clinical characteristics, which clearly hamper the impact of our conclusions. Additionally, the limited available evidence for ALK and KRAS mutations, makes it difficult to draw solid conclusions. Despite this,

482 our work gathers the most up-to-date and complete evidence (all models developed in 483 each of the studies were analyzed) on imaging-based models for the prediction of three 484 of the most important oncogene mutations in NSCLC, following a clinical approach and 485 a special focus on AI models. Our exhaustive review and meta-analyses are intended to 486 provide solid evidence for future research in the field. 487 In conclusion, radiomics-based models offer a useful and non-invasive method for 488 determining the status of EGFR mutations in NSCLC and seem to retain similar 489 predictive value for ALK and KRAS mutations. Additionally, although the inclusion of 490 clinical variables tends to increase the performance of the models, further validation is required. 492 **ACKNOWLEDGEMENTS** 493 494 **CONFLICTS OF INTEREST** 495 GJW reports personal fees from Quibim related to this work. He is a former employee 496 of SOTIO Biotech Inc., and reports personal fees from Imaging Endpoints II, 497 MiRanostics Consulting, Gossamer Bio, International Genomics Consortium, Angiex, 498 Genomic Health, Oncacare, Rafael Pharmaceuticals, Roche, Immunocore, Kymera, and 499 SPARC-all outside this submitted work; has ownership interest in MiRanostics 500 Consulting, Exact Sciences, Moderna, Agenus, Aurinia Pharmaceuticals, and 501 Circulogene-outside the submitted work; and has issued patents- all outside the 502 submitted work. The remaining authors declare no conflicts of interest. 503 **FUNDING** 504 **REFERENCES** 506 1 Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249. 508 509 2 Osmani L, Askin F, Gabrielson E et al. Current WHO guidelines and the critical 510 role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018; 52(Pt 1): 103-109.

491

505

507

511

513	3	König D,	Savic	Prince	S,	Rothschild	SI.	Targeted	therapy	in	advanced	and
-----	---	----------	-------	--------	----	------------	-----	----------	---------	----	----------	-----

- metastatic non-small cell lung cancer. An update on treatment of the most
- important actionable oncogenic driver alterations. *Cancers (Basel)*. 2021; 13(4).
- 516 4 Chiu YW, Kao YH, Simoff MJ et al. Costs of biopsy and complications in
- patients with lung cancer. *Clinicoecon Outcomes Res.* 2021; 13: 191-200.
- 518 5 Manicone M, Poggiana C, Facchinetti A et al. Critical issues in the clinical
- application of liquid biopsy in non-small cell lung cancer. *J Thorac Dis.* 2017;
- 520 9(Suppl 13): S1346-s1358.
- 521 6 Young M SR. Percutaneous lung lesion biopsy. [Updated 2023 Jun 19].
- 522 StatPearls [Internet]. . Treasure Island (FL): StatPearls Publishing.
- 523 7 Di Capua D, Bracken-Clarke D, Ronan K et al. The liquid biopsy for lung
- 524 cancer: state of the art, limitations and future developments. *Cancers (Basel)*.
- 525 2021; 13(16).
- Wu G, Jochems A, Refaee T et al. Structural and functional radiomics for lung
- 527 cancer. Eur J Nucl Med Mol Imaging. 2021; 48(12): 3961-3974.
- 528 9 Bera K, Braman N, Gupta A et al. Predicting cancer outcomes with radiomics
- and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022; 19(2): 132-
- 530 146.
- Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an
- updated guideline for reporting systematic reviews. *BMJ*. 2021; 372: n71.
- 533 11 Mongan J, Moy L, Kahn CE. Checklist for artificial intelligence in medical
- 534 imaging (CLAIM): a guide for authors and reviewers. *Radiol Artif Intell*. 2020;
- 535 2(2): e200029.
- Bossuyt PM, Reitsma JB. The STARD initiative. Lancet. 2003; 361(9351): 71.
- 537 13 Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate
- reporting of studies of diagnostic accuracy: the STARD initiative. *Radiology*.
- 539 2003; 226(1): 24-28.
- 540 14 Bossuyt PM, Reitsma JB, Bruns DE et al. STARD 2015: an updated list of
- essential items for reporting diagnostic accuracy studies. *Radiology*. 2015;
- 542 277(3): 826-832.
- 543 15 Cohen JF, Korevaar DA, Altman DG et al. STARD 2015 guidelines for reporting
- diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;
- 545 6(11): e012799.
- 546 16 Reitsma JB, Glas AS, Rutjes AW et al. Bivariate analysis of sensitivity and
- 547 specificity produces informative summary measures in diagnostic reviews. J
- 548 *Clin Epidemiol*. 2005; 58(10): 982-990.
- 549 17 Nair JKR, Saeed UA, McDougall CC et al. Radiogenomic models using
- machine learning techniques to predict EGFR mutations in non-small cell lung
- 551 cancer. Can Assoc Radiol J. 2021; 72(1): 109-119.
- 552 18 Shiri I, Maleki H, Hajianfar G et al. Next-generation radiogenomics sequencing
- for prediction of EGFR and KRAS mutation status in NSCLC patients using

554	multimodal imaging and machine learning algorithms. Mol Imaging Biol. 2020;
555	22(4): 1132-1148.

- Dang Y, Wang R, Qian K et al. Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer. *J Appl Clin Med Phys.* 2021; 22(1): 271-280.
- 559 20 Omura K, Murakami Y, Hashimoto K et al. Detection of EGFR mutations in 560 early-stage lung adenocarcinoma by machine learning-based radiomics. *Transl* 561 *Cancer Res.* 2023; 12(4): 837-847.
- Wang X, Kong C, Xu W et al. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature. *Thorac Cancer*. 2019; 10(10): 1904-1912.
- Liu Q, Sun D, Li N et al. Predicting EGFR mutation subtypes in lung adenocarcinoma using (18)F-FDG PET/CT radiomic features. *Transl Lung Cancer Res.* 2020; 9(3): 549-562.
- Yang L, Xu P, Li M et al. PET/CT radiomic features: a potential biomarker for EGFR mutation status and survival outcome prediction in NSCLC patients treated with TKIs. *Front Oncol*. 2022; 12: 894323.
- Hong D, Xu K, Zhang L et al. Radiomics signature as a predictive factor for EGFR mutations in advanced lung adenocarcinoma. *Front Oncol.* 2020; 10: 28.
- 573 25 Lu J, Ji X, Wang L et al. Machine learning-based radiomics for prediction of epidermal growth factor receptor mutations in lung adenocarcinoma. *Dis Markers*. 2022; 2022: 2056837.
- Wu S, Shen G, Mao J et al. CT radiomics in predicting EGFR mutation in nonsmall cell lung cancer: a single institutional study. *Front Oncol.* 2020; 10: 542957.
- 579 27 Yang C, Chen W, Gong G et al. Application of CT radiomics features to predict 580 the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung 581 adenocarcinoma. *Transl Cancer Res.* 2020; 9(11): 6683-6690.
- 582 Zhang L, Chen B, Liu X et al. Quantitative biomarkers for prediction of epidermal growth factor receptor mutation in non-small cell lung cancer. *Transl Oncol*. 2018; 11(1): 94-101.
- Zhu Y, Guo YB, Xu D et al. A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD). *Ann Transl Med.* 2021; 9(7): 545.
- Aide N, Weyts K, Lasnon C. Prediction of the presence of targetable molecular alteration(s) with clinico-metabolic (18) F-FDG PET radiomics in non-Asian lung adenocarcinoma patients. *Diagnostics (Basel)*. 2022; 12(10).
- 592 31 Li Y, Lu L, Xiao M et al. CT slice thickness and convolution Kernel affect 593 performance of a radiomic model for predicting egfr status in non-small cell 594 lung cancer: a preliminary study. *Sci Rep.* 2018; 8(1): 17913.

595	32	Zhu H, Song Y, Huang Z et al. Accurate prediction of epidermal growth factor
596		receptor mutation status in early-stage lung adenocarcinoma, using radiomics
597		and clinical features. Asia Pac J Clin Oncol. 2022; 18(6): 586-594.

- 598 33 Dong Y, Jiang Z, Li C et al. Development and validation of novel radiomics-599 based nomograms for the prediction of EGFR mutations and Ki-67 proliferation 600 index in non-small cell lung cancer. *Quant Imaging Med Surg.* 2022; 12(5): 601 2658-2671.
- Aerts HJ, Grossmann P, Tan Y et al. Defining a adiomic response phenotype: a pilot study using targeted therapy in NSCLC. *Sci Rep.* 2016; 6: 33860.
- Huang Q, Lu L, Dercle L et al. Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status. *J Med Imaging* (Bellingham). 2018; 5(1): 011005.
- Feng Y, Song F, Zhang P et al. Prediction of EGFR mutation status in non-small cell lung cancer based on ensemble learning. *Front Pharmacol*. 2022; 13: 897597.
- Huang X, Sun Y, Tan M et al. Three-dimensional convolutional neural networkbased prediction of epidermal growth factor receptor expression status in patients with non-small cell lung cancer. *Front Oncol.* 2022; 12: 772770.
- 513 Jia TY, Xiong JF, Li XY et al. Identifying EGFR mutations in lung 514 adenocarcinoma by noninvasive imaging using radiomics features and random 515 forest modeling. *Eur Radiol*. 2019; 29(9): 4742-4750.
- 616 39 Liu G, Xu Z, Ge Y et al. 3D radiomics predicts EGFR mutation, exon-19 617 deletion and exon-21 L858R mutation in lung adenocarcinoma. *Transl Lung* 618 *Cancer Res.* 2020; 9(4): 1212-1224.
- 619 40 Mei D, Luo Y, Wang Y et al. CT texture analysis of lung adenocarcinoma: can 620 Radiomic features be surrogate biomarkers for EGFR mutation statuses. *Cancer Imaging*. 2018; 18(1): 52.
- Zhang T, Xu Z, Liu G et al. Simultaneous identification of EGFR,KRAS,ERBB2, and TP53 mutations in patients with non-small cell lung cancer by machine learning-derived three-dimensional radiomics. *Cancers* (*Basel*). 2021; 13(8).
- Song J, Ding C, Huang Q et al. Deep learning predicts epidermal growth factor receptor mutation subtypes in lung adenocarcinoma. *Med Phys.* 2021; 48(12): 7891-7899.
- Wang C, Xu X, Shao J et al. Deep learning to predict EGFR mutation and PD-L1 expression status in non-small-cell lung cancer on computed tomography images. *J Oncol*. 2021; 2021: 5499385.
- Huang W, Wang J, Wang H et al. PET/CT based egfr mutation status classification of NSCLC using deep learning features and radiomics features.

  Front Pharmacol. 2022; 13: 898529.
- Kawazoe Y, Shiinoki T, Fujimoto K et al. Investigation of the combination of intratumoral and peritumoral radiomic signatures for predicting epidermal

- growth factor receptor mutation in lung adenocarcinoma. *J Appl Clin Med Phys.* 2023; 24(6): e13980.
- 639 46 Lu X, Li M, Zhang H et al. A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma. *Phys Med Biol.* 2020; 65(5): 055012.
- Wang J, Lv X, Huang W et al. Establishment and optimization of radiomics algorithms for prediction of KRAS gene mutation by integration of NSCLC gene mutation mutual exclusion information. *Front Pharmacol*. 2022; 13: 862581.
- 48 Yang X, Fang C, Li C et al. Can CT radiomics detect acquired T790M mutation and predict prognosis in advanced lung adenocarcinoma with progression after first- or second-generation EGFR TKIs? *Front Oncol.* 2022; 12: 904983.
- 649 49 Chang C, Zhou S, Yu H et al. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma. *Eur Radiol*. 2021; 31(8): 6259-6268.
- Dong Y, Hou L, Yang W et al. Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images. *Quant Imaging Med Surg.* 2021; 11(6): 2354-2375.
- Gao J, Niu R, Shi Y et al. The predictive value of [(18)F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma. *EJNMMI Res.* 2023; 13(1): 26.
- Huo JW, Luo TY, Diao L et al. Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma. *Front Oncol.* 2022; 12: 846589.
- Jiang M, Yang P, Li J et al. Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma. *Front Oncol.* 2022; 12: 985284.
- 665 54 Le NQK, Kha QH, Nguyen VH et al. Machine learning-based radiomics 666 signatures for EGFR and KRAS mutations prediction in non-small-cell lung 667 cancer. *Int J Mol Sci.* 2021; 22(17).
- 668 55 Li S, Li Y, Zhao M et al. Combination of (18)F-fluorodeoxyglucose PET/CT radiomics and clinical features for predicting epidermal growth factor receptor mutations in lung adenocarcinoma. *Korean J Radiol*. 2022; 23(9): 921-930.
- Li S, Luo T, Ding C et al. Detailed identification of epidermal growth factor
   receptor mutations in lung adenocarcinoma: Combining radiomics with machine
   learning. Med Phys. 2020; 47(8): 3458-3466.
- 674 57 Li X, Yin G, Zhang Y et al. Predictive power of a radiomic signature based on (18)F-FDG PET/CT images for EGFR mutational status in NSCLC. Front Oncol. 2019; 9: 1062.
- 677 58 Li XY, Xiong JF, Jia TY et al. Detection of epithelial growth factor receptor (EGFR) mutations on CT images of patients with lung adenocarcinoma using

- radiomics and/or multi-level residual convolutionary neural networks. *J Thorac Dis.* 2018; 10(12): 6624-6635.
- Liu Y, Zhou J, Wu J et al. Development and validation of machine learning models to predict epidermal growth factor receptor mutation in non-small cell lung cancer: a multi-center retrospective radiomics study. *Cancer Control*. 2022; 29: 10732748221092926.
- Ninomiya K, Arimura H, Chan WY et al. Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers. *PLoS One*. 2021; 16(1): e0244354.
- 689 61 Ninomiya K, Arimura H, Tanaka K et al. Three-dimensional topological 690 radiogenomics of epidermal growth factor receptor Del19 and L858R mutation 691 subtypes on computed tomography images of lung cancer patients. *Comput* 692 *Methods Programs Biomed*. 2023; 236: 107544.
- Rios Velazquez E, Parmar C, Liu Y et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. *Cancer Res.* 2017; 77(14): 3922-3930.
- Rossi G, Barabino E, Fedeli A et al. Radiomic detection of EGFR mutations in NSCLC. *Cancer Res.* 2021; 81(3): 724-731.
- 697 64 Tu W, Sun G, Fan L et al. Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. *Lung Cancer*. 2019; 132: 28-35.
- 700 65 Wang C, Ma J, Shao J et al. Predicting EGFR and PD-L1 status in NSCLC patients using multitask ai system based on CT images. *Front Immunol*. 2022; 13: 813072.
- Weng Q, Hui J, Wang H et al. Radiomic feature-based nomogram: a novel technique to predict EGFR-activating mutations for EGFR tyrosin kinase inhibitor therapy. *Front Oncol.* 2021; 11: 590937.
- 706 67 Yang X, Liu M, Ren Y et al. Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics nomogram analysis. *Eur Radiol*. 2022; 32(4): 2693-2703.
- 709 68 Zhang B, Qi S, Pan X et al. Deep CNN model using CT radiomics feature 710 mapping recognizes EGFR gene mutation status of lung adenocarcinoma. *Front* 711 *Oncol*. 2020; 10: 598721.
- 712 69 Zhang G, Cao Y, Zhang J et al. Predicting EGFR mutation status in lung 713 adenocarcinoma: development and validation of a computed tomography-based 714 radiomics signature. *Am J Cancer Res.* 2021; 11(2): 546-560.
- 715 70 Zhang M, Bao Y, Rui W et al. Performance of (18)F-FDG PET/CT radiomics for
   716 predicting EGFR mutation status in patients with non-small cell lung cancer.
   717 Front Oncol. 2020; 10: 568857.
- 718 71 Zhao HY, Su YX, Zhang LH et al. Prediction model based on 18F-FDG PET/CT 719 radiomic features and clinical factors of EGFR mutations in lung 720 adenocarcinoma. *Neoplasma*. 2022; 69(1): 233-241.

- 721 72 Chang C, Sun X, Wang G et al. A machine learning model based on PET/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma. *Front Oncol.* 2021; 11: 603882.
- 724 73 Ma DN, Gao XY, Dan YB et al. Evaluating solid lung adenocarcinoma 725 anaplastic lymphoma kinase gene rearrangement using noninvasive radiomics 726 biomarkers. *Onco Targets Ther*. 2020; 13: 6927-6935.
- 727 74 Song L, Zhu Z, Mao L et al. Clinical, conventional ct and radiomic feature-based 728 machine learning models for predicting ALK rearrangement status in lung 729 adenocarcinoma patients. *Front Oncol.* 2020; 10: 369.
- 730 75 Hendriks LE, Kerr KM, Menis J et al. Oncogene-addicted metastatic non-smallcell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2023; 34(4): 339-357.
- 733 76 Ettinger DS, Wood DE, Aisner DL et al. Non-Small Cell Lung Cancer, Version
   734 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2022; 20(5): 497-530.
- Ferry-Galow KV, Datta V, Makhlouf HR et al. What can be done to improve research biopsy quality in oncology clinical trials? *J Oncol Pract*. 2018; 14(11): Jop1800092.
- 739 78 Gutierrez ME, Choi K, Lanman RB et al. Genomic profiling of advanced non-740 small cell lung cancer in community settings: gaps and opportunities. *Clin Lung* 741 *Cancer*. 2017; 18(6): 651-659.
- 742 79 Fornacon-Wood I, Faivre-Finn C, O'Connor JPB et al. Radiomics as a personalized medicine tool in lung cancer: separating the hope from the hype.

  744 Lung Cancer. 2020; 146: 197-208.
- Neri E, Del Re M, Paiar F et al. Radiomics and liquid biopsy in oncology: the holons of systems medicine.
- 747 *Insights Imaging*. 2018; 9(6): 915-924.
- Nguyen HS, Ho DKN, Nguyen NN et al. Predicting EGFR mutation status in non-small cell lung cancer using artificial intelligence: a systematic review and meta-analysis. *Acad Radiol*. 2023.
- 751 82 Steinert HC. PET and PET-CT of lung cancer. *Methods Mol Biol*. 2011; 727: 33-752 51.
- 753 83 Alwosheel A, van Cranenburgh S, Chorus CG. Is your dataset big enough? 754 Sample size requirements when using artificial neural networks for discrete 755 choice analysis. *J Choice Model*. 2018; 28: 167-182.
- Rajput D, Wang W-J, Chen C-C. Evaluation of a decided sample size in machine learning applications. *BMC Bioinformatics*. 2023; 24(1): 48.
- 758 85 Mu W, Jiang L, Zhang J et al. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. *Nat Commun.* 2020; 11(1): 5228.
- 760 86 Zhao W, Yang J, Ni B et al. Toward automatic prediction of EGFR mutation
   761 status in pulmonary adenocarcinoma with 3D deep learning. *Cancer Med.* 2019;
   762 8(7): 3532-3543.

- 763 87 Zuo Y, Liu Q, Li N et al. Optimal (18)F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study. *Front Oncol.* 2023; 13: 1173355.
- 766 88 Shiri I, Amini M, Nazari M et al. Impact of feature harmonization on radiogenomics analysis: prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images. *Comput Biol Med.* 2022; 142: 105230.
- 769 89 Yip SSF, Parmar C, Kim J et al. Impact of experimental design on PET radiomics in predicting somatic mutation status. *Eur J Radiol*. 2017; 97: 8-15.
- 771 90 Shao J, Ma J, Zhang S et al. Radiogenomic system for non-invasive 772 identification of multiple actionable mutations and PD-L1 expression in non-773 small cell lung cancer based on ct images. *Cancers (Basel)*. 2022; 14(19).
- 774 91 Xiao Z, Cai H, Wang Y et al. Deep learning for predicting epidermal growth factor receptor mutations of non-small cell lung cancer on PET/CT images.

  776 Ouant Imaging Med Surg. 2023; 13(3): 1286-1299.
- 777 92 Agüloğlu N, Aksu A, Akyol M et al. Importance of pretreatment 18F-FDG 778 PET/CT texture analysis in predicting EGFR and ALK mutation in patients with 779 non-small cell lung cancer. *Nuklearmedizin*. 2022; 61(6): 433-439.
- 780 93 Agazzi GM, Ravanelli M, Roca E et al. CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer. *Radiol Med.* 2021; 126(6): 786-794.
- 783 94 Chen W, Hua Y, Mao D et al. A computed tomography-derived radiomics approach for predicting uncommon EGFR mutation in patients with NSCLC. *Front Oncol.* 2021; 11: 722106.
- 786 95 Chen Q, Li Y, Cheng Q et al. EGFR mutation status and subtypes predicted by CT-based 3D radiomic features in lung adenocarcinoma. *Onco Targets Ther*. 2022; 15: 597-608.
- 789 96 Choe J, Lee SM, Kim W et al. CT radiomics-based prediction of anaplastic lymphoma kinase and epidermal growth factor receptor mutations in lung adenocarcinoma. *Eur J Radiol*. 2021; 139: 109710.
- 792 97 Digumarthy SR, Padole AM, Gullo RL et al. Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? *Medicine (Baltimore)*. 2019; 98(1): e13963.
- 795 98 Hao P, Deng BY, Huang CT et al. Predicting anaplastic lymphoma kinase
   796 rearrangement status in patients with non-small cell lung cancer using a machine
   797 learning algorithm that combines clinical features and CT images. Front Oncol.
   798 2022; 12: 994285.
- He R, Yang X, Li T et al. A machine learning-based predictive model of epidermal growth factor mutations in lung adenocarcinomas. *Cancers (Basel)*. 2022; 14(19).
- Hou D, Li W, Wang S et al. Different clinicopathologic and computed tomography imaging characteristics of primary and acquired EGFR T790M mutations in patients with non-small-cell lung cancer. *Cancer Manag Res.* 2021; 13: 6389-6401.

806	101	Jiang M, Zhang Y, Xu J et al. Assessing EGFR gene mutation status in non-small
807		cell lung cancer with imaging features from PET/CT. Nucl Med Commun. 2019;
808		40(8): 842-849.

- 809 102 Kawazoe Y, Shiinoki T, Fujimoto K et al. Comparison of the radiomics-based 810 predictive models using machine learning and nomogram for epidermal growth 811 factor receptor mutation status and subtypes in lung adenocarcinoma. *Phys Eng* 812 *Sci Med.* 2023; 46(1): 395-403.
- Koyasu S, Nishio M, Isoda H et al. Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on (18)F FDG-PET/CT. *Ann Nucl Med.* 2020; 34(1): 49-57.
- Li S, Ding C, Zhang H et al. Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer. *Med Phys.* 2019; 46(10): 4545-4552.
- Li H, Gao C, Sun Y et al. Radiomics analysis to enhance precise identification of epidermal growth factor receptor mutation based on positron emission tomography images of lung cancer patients. *J Biomed Nanotechnol*. 2021; 17(4): 691-702.
- Liu Y, Kim J, Balagurunathan Y et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. *Clin Lung Cancer*. 2016; 17(5): 441-448.e446.
- Liu Z, Zhang T, Lin L et al. Applications of radiomics-based analysis pipeline
   for predicting epidermal growth factor receptor mutation status. *Biomed Eng Online*. 2023; 22(1): 17.
- Lu L, Sun SH, Yang H et al. Radiomics prediction of EGFR status in lung cancer-our experience in using multiple feature extractors and The Cancer Imaging Archive Data. *Tomography*. 2020; 6(2): 223-230.
- Ruan D, Fang J, Teng X. Efficient 18F-Fluorodeoxyglucose positron emission tomography/computed tomography-based machine learning model for predicting epidermal growth factor receptor mutations in non-small cell lung cancer. *Q J Nucl Med Mol Imaging*. 2022.
- Trivizakis E, Souglakos J, Karantanas A et al. Deep radiotranscriptomics of nonsmall cell lung carcinoma for assessing molecular and histology subtypes with a data-driven analysis. *Diagnostics (Basel)*. 2021; 11(12).
- Yamazaki M, Yagi T, Tominaga M et al. Role of intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer. Br J Radiol. 2022; 95(1140): 20220374.
- Yang B, Ji HS, Zhou CS et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma. *Transl Lung Cancer Res.* 2020; 9(3): 563-574.
- Zhang J, Zhao X, Zhao Y et al. Value of pre-therapy (18)F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. *Eur J Nucl Med Mol Imaging*. 2020; 47(5): 1137-1146.

848 849 850	114	Zhang T, Liu Z, Lin L et al. Detection of the gene mutation of epidermal growth factor receptor in lung adenocarcinoma by radiomic features from a small amount of PET data. <i>Nucl Med Commun</i> . 2023.
851 852 853	115	Zhao W, Wu Y, Xu Y et al. The potential of radiomics nomogram in non-invasively prediction of epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma. <i>Front Oncol.</i> 2019; 9: 1485.
854		

**Table 1.** Methodological characteristics of the studies (N = 89) included in the systematic review. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally indicate those that were included in the different meta-analyses and consequently, that are represented in the forest plots.

Author-Year	Imaging	Contrast-CT*	T	Madal	Classifier		Datasets		
	modality	Contrast CT	Tumor segmentation	Model	(ML)	Training	Validation	Test	Partition strategy
Agüloğlu et al. 2022 <sup>92</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	RF NB KNN DT SVM LR	133	56	_	Training-Validation allowed without perm
Aerts et al. 2016 <sup>34</sup>	СТ	Non-contrast CT	Semi-automatic	Classical statistical model	_	_	_	_	ermission.
Agazzi et al. 2021 <sup>93</sup>	СТ	Contrast-enhanced	Manual	ML	GBM	104	67	_	Training-Validation split

Aide et al. 2022 <sup>30</sup>	PET	_	Manual	ML	LASSO	87	22	_	Training-Validation split
Chang et al. 2021# <sup>49</sup>	PET/CT	Non-contrast CT	Manual	ML	LASSO	409	174	_	Training-Validation split
Chang et al. 2021## <sup>72</sup>	PET/CT	Non-contrast CT	Manual	ML	$LR^{\dagger}$	367	159	_	Training-Validation
Chen et al. 2021 <sup>94</sup>	СТ	Non-contrast CT	Manual	ML	SVM	179	44	_	Training-Validation split
Chen et al. 2022 <sup>95</sup>	СТ	Non-contrast CT	Semi-automatic	ML	LASSO	176	57	_	Training-Validation
Choe et al. 2021 <sup>96</sup>	СТ	Contrast-enhanced	Semi-automatic	ML	LR	349	154	_	Training-Validation split
Dang et al. 2021 <sup>19</sup>	СТ	Non-contrast CT	Semi-automatic	ML	LASSO	88	30	-	Training-Validation split
Digumarthy et	СТ	Contrast-enhanced	Not specified	Classical	-	_	-	_	-

al. 2019 <sup>97</sup>				statistical model					
Dong et al. 2022 <sup>33</sup>	СТ	Non-contrast CT	Not specified	ML	LR	87	45	_	Training-Validation split
Dong et al. 2021 <sup>50</sup>	СТ	Non-contrast CT	Manual	DL ML	RF	363	162	-	Training-Validation
Feng et al. 2022 <sup>36</sup>	СТ	Non-contrast CT	Manual	ML	RF XGBoost LR SVM	151	_	_	Training-Validation Split Split
Gao et al. 2023 <sup>51</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR RF SVM	404	111	_	Training-Validation split permission
Hao et al. 2022 <sup>98</sup>	СТ	Non-contrast CT	Manual	ML	SVM XGBoost AdaBoost LBP DT	154	39	-	Training-Validation split

					LR				
He et al. 2022 <sup>99</sup>	СТ	Non-contrast CT	Semi-automatic	ML	RF KNN LGBM SVM	-	_	_	Training-Validation split
Hong et al. 2020 <sup>24</sup>	СТ	Contrast-enhanced	Manual	ML	NBC KNN RF SVM DT LR	140	61	-	Training-Validation split split
Huang et al. 2018 <sup>35</sup>	СТ	Non-contrast CT	Semi-automatic	Classical statistical model	-	_	_	_	- House
Huang et al. 2022 <sup>44</sup>	PET/CT	Non-contrast CT	Manual	DL ML	LR	138	57	_	Training-Validation split
Huang et al. 2022 <sup>37</sup>	СТ	Non-contrast CT	Manual	DL	LR	770	304	_	Training-Validation split

				ML					
Huo et al. 2022 <sup>52</sup>	СТ	Contrast-enhanced	Manual	ML	GBT	487	121	_	Training-Validation split
Hou et al. 2021 <sup>100</sup>	СТ	Contrast-enhanced	Semi-automatic	Classical statistical model	_	144	62	_	Training-Validation
Jia et al. 2019 <sup>38</sup>	СТ	Non-contrast CT	Semi-automatic	ML	RF	345	158	_	Training-Validation
Jiang et al. 2019 <sup>101</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	SVM	_	_	_	10-fold cross- validation  Training-Validation split
Jiang et al. 2022 <sup>53</sup>	СТ	Non-contrast CT	Manual	ML	SVM	514	178	_	Training-Validation
Kawazoe et al. 2023 <sup>45</sup>	СТ	Non-contrast CT	Semi-automatic	ML	SVM LR LGBM	120	44	_	Training-Validation split
Kawazoe et al.	СТ	Non-contrast CT	Semi-automatic	ML	SVM	120	52	_	Training-Validation

2023 <sup>102</sup>					LR				split
Koyasu et al. 2020 <sup>103</sup>	PET/CT	Non-contrast CT	Manual	ML	RF XGBoost	-	-	_	10-fold cross- validation
Le et al. 2021 <sup>54</sup>	СТ	Non-contrast CT	Manual	ML	XGBoost	143	18	_	Training-Validation  split  \$\bar{\bar{\bar{\bar{\bar{\bar{\bar{\bar
Li et al. 2018# <sup>58</sup>	СТ	Non-contrast CT	Manual	DL ML	RF	810	200	_	Training-Validation split
Li et al. 2018 <sup>31</sup>	СТ	Contrast-enhanced	Semi-automatic	ML	SVM	_	-	_	3-fold cross-
Li et al 2019# <sup>57</sup>	PET/CT	Non-contrast CT	Manual	ML	Boosting ML scheme	115	_	_	10-fold cross-
Li et al. 2019 <sup>104</sup>	СТ	Non-contrast CT	Manual	ML	LR	236	76	_	Training-Validation split
Li et al. 2020 <sup>56</sup>	СТ	Non-contrast CT	Manual	ML	LR SVM	326	112	_	Training-Validation split

					RF NB Neural network				
Li et al. 2021 <sup>105</sup>	PET	_	Semi-automatic	ML	SVM	50	25	-	Training-Validation split
Li et al. 2022 <sup>55</sup>	PET/CT	Non-contrast CT	Manual	ML	LR	125	54	_	Training-Validation
Liu et al. 2016 <sup>106</sup>	СТ	Non-contrast CT	Semi-automatic	Classical statistical model	-	-	ı	_	No reuse allo
Liu et al. 2020# <sup>39</sup>	СТ	Contrast-enhanced	Semi-automatic	ML	LR	210	53	_	Training-Validation split
Liu et al. 2020 <sup>22</sup>	PET/CT	Non-contrast CT	Manual	ML	XGBoost	111	37	_	Training-Validation split
Liu et al. 2022 <sup>59</sup>	CT	Non-contrast CT	Manual	ML	LR DT RF	296	50	-	Training-Validation split

					SVM				
Liu et al. 2023 <sup>107</sup>	PET/CT	Non-contrast CT	Manual	ML	LR DT RF SVM	_	_	_	10-fold cross- validation
Lu et al. 2020# <sup>46</sup>	СТ	Non-contrast CT	Manual	ML	LR	83	_	21	Training-Validation
Lu et al. 2020 <sup>108</sup>	СТ	Non-contrast CT	Semi-automatic	ML	KNN Bagging SVM RF	105	228	_	Training-Validation split split wed without permission
Lu et al. 2022 <sup>25</sup>	СТ	Non-contrast CT	Manual	ML	DT AdaBoost NB RF LR SVM XGBoost	140	61	-	Training-Validation split

					KNN				
Ma et al. 2020 <sup>73</sup>	СТ	Contrast-enhanced	Manual	ML	SVM	98	42	_	Training-Validation split
Mei et al. 2018 <sup>40</sup>	СТ	Non-contrast CT	Manual	Classical statistical model	-	_	_	_	All rights
Mu et al. 2020 <sup>85</sup>	PET/CT	Non-contrast CT	Manual	DL	-	429	187	65	Training-Validation
Nair et al. 2021 <sup>17</sup>	PET/CT	Contrast-enhanced	Manual	ML	LR	_	_	_	split  LOOCV  LOOCV  Training-Validation  split  Training-Validation
Ninomiya et al. 2021 <sup>60</sup>	СТ	Contrast-enhanced	Manual	ML	SVM	99 <sup>‡</sup>	99 <sup>‡</sup>	95	Training-Validation
Ninomiya et al. 2023 <sup>61</sup>	СТ	Contrast-enhanced	Not specified	ML	SVM	92	62	_	Training-Validation split
Omura et al. 2023 <sup>20</sup>	СТ	Contrast-enhanced	Automatic	ML	RF	_	_	_	Training-Validation split

Ríos Velázquez et al. 2017 <sup>62</sup>	СТ	Contrast + Non- contrast CT	Semi-automatic	ML	RF	353	352	_	Training-Validation split
Rossi et al. 2021 <sup>63</sup>	СТ	Non-contrast CT	Manual	ML	SVM	-	109	61	Training-Validation split
Ruan et al. 2022 <sup>109</sup>	PET/CT	Non-contrast CT	Manual	ML	SVM	70	30	_	Training-Validation
Shao et al. 2022 <sup>90</sup>	СТ	Non-contrast CT	Semi-automatic	DL	_	_	_	_	Training-Validation
Shiri et al. 2020 <sup>18</sup>	CT low dose CTD PET/CT	Contrast-enhanced	Manual Automatic <sup>§</sup>	ML	SVM KNN DT QDA MLP SGD LR NB GNB	82	68	_	10-fold cross-validation

					RF AdaBoost Bagging				
Shiri et al. 2022 <sup>88</sup>	PET/CT	Non-contrast CT	Manual Automatic <sup>§</sup>	ML	RF	-	-	_	Training-Validation
Song et al. 2021 <sup>42</sup>	СТ	Not specified	Manual Automatic	DL ML	SVM	528	137	_	Training-Validation
Song et al. 2020 <sup>74</sup>	СТ	Non-contrast CT	Automatic	ML	DT	268	67	_	Training-Validation
Trivizakis et al. 2021 <sup>110</sup>	СТ	Not specified	Not specified	DL ML	KNN DT RBF-GPC RBF-SVM Linear SVM Polynomial SVM Sigmoid SVM	-	l	-	5-fold cross-validation

	Т		1			T		т	
Tu et al. 2019 <sup>64</sup>	СТ	Non-contrast CT	Not specified	ML	LR	243	161	_	Training-Validation split
Wang et al. 2019 <sup>21</sup>	СТ	Contrast-enhanced	Manual	ML	SVM	41	_	_	Training-Validation split
Wang et al. 2021 <sup>43</sup>	СТ	Non-contrast CT	Manual	DL	-	882	125	255	Training-Validation split
Wang et al. 2022# <sup>65</sup>	СТ	Non-contrast CT	Manual	DL ML	LASSO	-	_	-	Training-Validation
Wang et al. 2022## <sup>47</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR	180	78	_	Training-Validation
Weng et al. 2021 <sup>66</sup>	СТ	Non-contrast CT	Semi-automatic	ML	LR	210	91	_	Training-Validation
Wu et al. 2020 <sup>26</sup>	СТ	Contrast-enhanced	Manual	ML	LR	_	_	_	10-fold cross- validation
Xiao et al.	PET/CT	Non-contrast CT	Manual	DL	RF	121	29	-	Training-Validation

2023 <sup>91</sup>				ML					split
Yamazaki et al. 2022 <sup>111</sup>	СТ	Non-contrast CT	Semi-automatic	ML	RF	-	-	-	-
Yang et al. 2020# <sup>27</sup>	СТ	Contrast-enhanced	Semi-automatic	ML	LASSO	130	40	_	Training-Validation  split  □
Yang et al. 2020 <sup>112</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	RF	139	35	_	Training-Validation
Yang et al. 2022# <sup>67</sup>	СТ	Contrast + Non- contrast CT	Manual	ML	LR RF SVM GBT NB	327	66	19	Training-Validation split split
Yang et al. 2022 <sup>23</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	SVM DT RF	218	95	-	Training-Validation split
Yang et al.	СТ	Contrast-enhanced	Manual	ML	LR	176	74	_	Training-Validation

2022 <sup>48</sup>									split
Yip et al. 2017 <sup>89</sup>	PET	-	Manual	Classical statistical model	-	_	-	-	-
Zhang et al. 2018 <sup>28</sup>	СТ	Non-contrast CT	Manual	ML	LR	140	40	-	Training-Validation split
Zhang et al. 2020# <sup>70</sup>	PET/CT	Non-contrast CT	Manual	ML	RF SVM LR	_	_	-	10-fold cross- validation
Zhang et al. 2020 <sup>113</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR	175	73	-	Training-Validation split
Zhang et al. 2020## <sup>68</sup>	СТ	Non-contrast CT	Semi-automatic	DL ML	RF SVM	638	71	205	Training-Validation split
Zhang et al.	СТ	Contrast-enhanced	Semi-automatic	ML	LASSO	_	_	_	Training-Validation

202141									split
Zhang et al. 2021 <sup>69</sup>	СТ	Non-contrast CT	Manual	ML	DT LR SVM Multivariate analysis for C- R-R model	294	126	-	Training-Validation split
Zhang et al. 2023 <sup>114</sup>	PET	_	Manual	ML	SVM RF LR AdaBoost	-	_	_	10-fold cross- validation
Zhao et al. 2019 <sup>86</sup>	СТ	Non-contrast CT	Manual	DL ML	LR	348	116	116	Training-Validation split
Zhao et al. 2019 <sup>115</sup>	СТ	Non-contrast CT	Manual	ML	LR	322	315	_	Training-Validation split
Zhao et al. 2022 <sup>71</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR	65	23	_	Training-Validation split

Zhu et al. 2022 <sup>32</sup>	СТ	Non-contrast CT	Semi-automatic	ML	LASSO RF SVM	875	217	_	Training-Validation split
Zhu et al. 2021 <sup>29</sup>	СТ	Contrast-enhanced	Manual	ML	SVM KNN RF LR	159	40	_	Training-Validation split
Zuo et al. 2023 <sup>87</sup>	PET/CT	Non-contrast CT	Manual	ML	LGBM XGBoost RF LR	410	170	180	Training-Validation split

<sup>\*</sup>In studies in which PET/CT was performed, only details about contrast were provided for PET acquisition. Consequently, it was assumed that CT scans were non-contrast enhanced.

### ¶80% Training-Validation split.

CT, computed tomography; CTD, contrast-enhanced diagnostic quality; DL, deep learning; DT, decision tree; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2;

<sup>†</sup>Not specified but inferred from the methodology and results.

<sup>‡</sup>Number of cases for training and validation sets not specified; only a total number for both cohorts provided.

<sup>§</sup>Manual segmentation for PET images; automatic segmentation for CT images.

44

GBM, gradient boosted machine; GBT, gradient boosting tree; GNB, Gaussian Naives Bayes; GPC, Gaussian processes classification; LASSO, least absolute shrinkage and selection operator; LBP, local binary pattern; LGBM, Light gradient boosted machine; LOOCV, leave-one-out cross-validation; LR, logistic regression; ML, machine learning; MLP, multilayer perceptron; NB, Naive Bayes; KNN, K-nearest neighbors; PET, positron emission tomography; QDA, quadratic discriminant analysis; RBF, radial basis function; RF, random forest; SGD, stocastic gradient descendent; SVM, support vector machine; TP53, tumor suppressor protein 53.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.31.24308261; this version posted May 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

**Table 2.** Clinical characteristics of the studies (N = 89) included in the systematic review. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally indicate those that were included in the different meta-analyses and consequently, that are represented in the forest plots.

	Target		Total	Se	X			Smokin	g status		
Author-Year	oncogene mutation	Design	of patien ts	Female	Male	Age Mean/median	Histology	Current /former smoker	Non- smoker	TNM stage	Treatment
Agüloğlu et al. 2022 <sup>92</sup>	EGFR ALK	Unicentric	189	59	130	62/–	NSCLC	130	59	Stages I-IV	Naïve
Aerts et al. 2016 <sup>34</sup>	EGFR	Unicentric	47	-	_	-/-	NSCLC	-	_	_	Naïve + post- treatment images
Agazzi et al. 2021 <sup>93</sup>	EGFR ALK	Unicentric	84	39	45	-/63	ADC	57	27	_	Naïve
Aide et al. 2022 <sup>30</sup>	EGFR	Unicentric	109	34	75	-/66	ADC	96	13	Stages II-IV	Naïve

Chang et al. 2021# <sup>49</sup>	EGFR	Unicentric	583	305	278	-/62	ADC	229	354	Stages I-III	Naïve
Chang et al. 2021## <sup>72</sup>	ALK	Unicentric	526	272	254	-/58.25	ADC	202	324	Stages I-IV	Naïve
Chen et al. 2021 <sup>94</sup>	EGFR	Unicentric	223	109	114	64.63/–	NSCLC	55	168	Stages I-IV	Naïve d
Chen et al. 2022 <sup>95</sup>	EGFR	Unicentric	233	105	128	57.5/-	ADC	65	168	Stages I-IV	Naïve
Choe et al. 2021 <sup>96</sup>	ALK	Unicentric	503	273	230	62.5/–	ADC	200	303	Stages I-IV	Not specified
Dang et al. 2021 <sup>19</sup>	EGFR	Not specified	118	55	63	63.82/–	ADC, SCC	_	_	Stages I-III	No treatment*
Digumarthy et al. 2019 <sup>97</sup>	EGFR	Unicentric	93	50	43	60/–	ADC, SCC	61	32	_	Naïve
Dong et al. 2022 <sup>33</sup>	EGFR	Multicentric	132	64	68	58.8/-	NSCLC	42	90	Stages I-III	Naïve
Dong et al.	EGFR	Multicentric	525	250	275	<b>-/65.5</b>	NSCLC	373	152	_	Not specified

2021 <sup>50</sup>	KRAS										
Feng et al. 2022 <sup>36</sup>	EGFR	Multicentric	168	_	_	-/-	NSCLC	_	_	-	Not specified <sup>†</sup>
Gao et al. 2023 <sup>51</sup>	EGFR	Unicentric	515	264	251	64/-	ADC	175	_	Stages I-IV	Naïve
Hao et al. 2022 <sup>98</sup>	ALK	Unicentric	193	102	91	54.26/-	NSCLC	49	144	Stages II and IV	Naïve d
He et al. 2022 <sup>99</sup>	EGFR	Multicentric	758	317	441	55.6/-	NSCLC	358	400	Stages I-IV	Naïve
Hong et al. 2020 <sup>24</sup>	EGFR	Unicentric	201	94	107	58.12/-	ADC	64	137	Stages I-IV	Naïve
Huang et al. 2018 <sup>35</sup>	EGFR	Unicentric	46	_	-	-/-	NSCLC	-	_	-	Naïve + post- treatment images
Huang et al. 2022 <sup>44</sup>	EGFR	Unicentric	195	72	123	61.14 –	NSCLC	127	68	-	No treatment*
Huang et al. 2022 <sup>37</sup>	EGFR	Unicentric	1074	_	_	-/-	NSCLC	_	_	-	Not specified

Huo et al. 2022 <sup>52</sup>	EGFR	Unicentric	608	272	336	61.7/–	ADC	0	335	Stages II and IV	Naïve
Hou et al. 2021 <sup>100</sup>	EGFR	Unicentric	206	120	86	-/59	ADC, SCC, ASC‡	57	_	Stages I-IV	Naïve
Jia et al. 2019 <sup>38</sup>	EGFR	Unicentric	503	249	254	-/60.5	ADC	80	423	Stages I-IV	Not specified <sup>†</sup>
Jiang et al. 2019 <sup>101</sup>	EGFR	Unicentric	80	32	48	64/62.5	NSCLC	21	59	-	Naïve
Jiang et al. 2022 <sup>53</sup>	EGFR	Unicentric	692	-	_	59/-	ADC	_	_	_	Naïve
Kawazoe et al. 2023 <sup>45</sup>	EGFR	Unicentric	164	75	89	70.24/–	ADC	102	62	Stages I-IV	No treatment <sup>§</sup>
Kawazoe et al. 2023 <sup>102</sup>	EGFR	Unicentric	172	77	95	70.76/–	ADC	107	65	Stages I-IV	Naïve
Koyasu et al. 2020 <sup>103</sup>	EGFR	Unicentric	138	54	84	67.8/–	ADC, SCC	_	_	-	Not specified

Le et al. 2021 <sup>54</sup>	EGFR KRAS	Multicentric	161	50	111	68.05/–	ADC, NSCLC NOS, SCC	61	100	_	Naïve
Li et al. 2018# <sup>58</sup>	EGFR	Unicentric	1010	457	553	-/63	ADC	262	748	Stages I-IV	Naïve
Li et al. 2018 <sup>31</sup>	EGFR	Unicentric	51	19	32	58.1/–	ADC	24	27	Stages I-III	Not specified †
Li et al 2019# <sup>57</sup>	EGFR	Unicentric	115	62	53	-/63	NSCLC	36	79	Stages II and IV	Not specified†
Li et al. 2019 <sup>104</sup>	EGFR	Unicentric	312	164	148	Freq./Freq. <sup>1</sup>	ADC, SCC	109	203	Stages II and IV	Naïve allowed with the state of the specified Naïve Not specified Not specified
Li et al. 2020 <sup>56</sup>	EGFR	Multicentric	438	_	_	61.31/–	ADC	_	_	_	Naïve
Li et al. 2021 <sup>105</sup>	EGFR	Unicentric	75	45	30	62/–	Lung cancer**	34	41	-	Not specified Not specified
Li et al. 2022 <sup>55</sup>	EGFR	Unicentric	179	103	76	61.51/59.5	ADC	65	114	_	Naïve
Liu et al. 2016 <sup>106</sup>	EGFR	Unicentric	298	172	126	-/60	ADC, Others	136	162	Stages II and IV	Naïve

Liu et al. 2020# <sup>39</sup>	EGFR	Unicentric	263	121	142	62.5/–	ADC	31	232	_	Not specified <sup>†</sup>
Liu et al. 2020 <sup>22</sup>	EGFR	Unicentric	148	63	85	-/61.2	ADC	_	_	Stages II-IV	Naïve
Liu et al. 2022 <sup>59</sup>	EGFR	Multicentric	346	141	205	66.69/–	ADC, SCC, LCC, PSC	225	121	_	Naïve .
Liu et al. 2023 <sup>107</sup>	EGFR	Unicentric	115	62	53	-/62.75	ADC	36	79	Stages I-IV	Naïve
Lu et al. 2020# <sup>46</sup>	EGFR	Unicentric	104	64	40	58.27/-	ADC	30	74	Stages I-IV	No treatment*
Lu et al. 2020 <sup>108</sup>	EGFR	Multicentric	228 <sup>††</sup>	85 <sup>††</sup>	120 <sup>††</sup>	67.94/–	ADC, SCC, NOS	_	-	Stages 0-IV	Not specified
Lu et al. 2022 <sup>25</sup>	EGFR	Unicentric	201	99	102	64.81/–	ADC	84	117	Stages III-IV	Naïve
Ma et al. 2020 <sup>73</sup>	ALK	Unicentric	140	87	53	54.19/–	ADC	45	95	Stages II and IV	Naïve
Mei et al. 2018 <sup>40</sup>	EGFR	Unicentric	296	144	152	58.56/-	ADC	86	210	_	Not specified <sup>†</sup>

Mu et al. 2020 <sup>85</sup>	EGFR	Multicentric	681	303	378	61,83/–	ADC, SCC	315	366	Stages I-IV	Naïve
Nair et al. 2021 <sup>17</sup>	EGFR	Unicentric	50	18	32	-/-	NSCLC	35	15	_	Naïve
Ninomiya et al. 2021 <sup>60</sup>	EGFR	Multicentric	194	74	120	-/67	NSCLC	128	66	Stages I-IV	Not specified
Ninomiya et al. 2023 <sup>61</sup>	EGFR	Multicentric	154	86	68	-/67	Lung	73	81	Stages I-IV	Not specified
Omura et al. 2023 <sup>20</sup>	EGFR	Unicentric	99	65	34	66/	ADC	41	-	Stages I-II	Naïve
Ríos Velázquez et al. 2017 <sup>62</sup>	EGFR KRAS	Multicentric	763	459	304	65/–	ADC	548	215	Stages I-IV	Not specified
Rossi et al.	EGFR	Multicentric	170	_	_	-/-	ADC	110	30	_	Naïve

2021 <sup>63</sup>											
Ruan et al. 2022 <sup>109</sup>	EGFR	Unicentric	100	42	58	- / 64.5	NSCLC	33	67	Stages I-IV	Naïve
Shao et al. 2022 <sup>90</sup>	EGFR	Unicentric	1096	-	_	58.26/-	NSCLC	_	_	-	Naïve
Shiri et al. 2020 <sup>18</sup>	EGFR KRAS	Unicentric	150	_	_	69.1 –	ADC, SCC, NOS <sup>‡</sup>	_	_	-	Not specified
Shiri et al. 2022 <sup>88</sup>	EGFR KRAS	Multicentric	136	-	_	-/-	ADC, SCC, NOS	_	_	-	Not specified
Song et al. 2021 <sup>42</sup>	EGFR	Multicentric	665	336	329	Freq./Freq.¶	ADC	334	331	Stages II and IV	Not specified <sup>‡‡</sup>
Song et al. 2020 <sup>74</sup>	ALK	Unicentric	335	196	139	57 / –	ADC	103	232	Stages I-IV	Naïve

Trivizakis et al. 2021 <sup>110</sup>	EGFR	Unicentric	112	_	_	-/-	ADC, SCC	-	_	-	Not specified
Tu et al. 2019 <sup>64</sup>	EGFR	Unicentric	404	211	193	59.95/-	NSCLC	114	290	Stages II and IV	Naïve
Wang et al. 2019 <sup>21</sup>	EGFR	Unicentric	51	35	16	58.45/-	ADC	9	42	Stages 0-II	Not specified
Wang et al. 2021 <sup>43</sup>	EGFR PD-L1	Unicentric	1262	642	620	57.7/-	ADC, SCC, Others <sup>‡</sup>	452	749	Stages I-IV	Not specified <sup>§§</sup>
Wang et al. 2022# <sup>65</sup>	EGFR PD-L1	Unicentric	3629	1674	1955	59.29/–	ADC, SCC, Others	1413	1981	Stages I-IV	Naïve 5
Wang et al. 2022## <sup>47</sup>	KRAS	Unicentric	258	78	180	62.35/–	NSCLC	166	92	-	No treatment*
Weng et al. 2021 <sup>66</sup>	EGFR	Unicentric	301	145	156	64.95/–	NSCLC	110	191	-	Naïve

Wu et al. 2020 <sup>26</sup>	EGFR	Unicentric	67	29	38	56.35/-	ADC, SCC	34	33	Stages III-IV	Naïve
Xiao et al. 2023 <sup>91</sup>	EGFR	Unicentric	150	59	91	-/58	NSCLC	64	86	_	Not specified
Yamazaki et al. 2022 <sup>111</sup>	EGFR	Unicentric	478	190	288	Freq./Freq.¶	ADC, SCC, Others <sup>‡</sup>	_	_	Stages II and IV	Naïve
Yang et al. 2020# <sup>27</sup>	EGFR	Unicentric	253	155	98	-/62	ADC	105	148	Stages III-IV	Naïve
Yang et al. 2020 <sup>112</sup>	EGFR	Unicentric	174	81	93	61.72/–	ADC	59	115	Stages II and IV	Naïve
Yang et al. 2022# <sup>67</sup>	EGFR	Unicentric	412	223	189	62/–	ADC, SCC	105	307	-	Naïve
Yang et al. 2022 <sup>23</sup>	EGFR	Unicentric	313	164	149	59.21/–	ADC	105	208	Stages II-IV	Naïve
Yang et al. 2022 <sup>48</sup>	EGFR	Unicentric	250	-	_	56.35 / –	ADC	_	_	-	Treated with TKIs <sup>¶</sup>

Yip et al. 2017 <sup>89</sup>	KRAS	Unicentric	348	214	134	-/6 <b>5</b>	ADC, NSCLC NOS, SC. Not available for 1 patient <sup>‡</sup>	286	62	Stages I-IV	Naïve G
Zhang et al. 2018 <sup>28</sup>	EGFR	Unicentric	180	46	134	59.7/–	ADC, SCC, Others	119	61	Stages III-IV	Naïve
Zhang et al. 2020# <sup>70</sup>	EGFR	Unicentric	173	58	115	60.8/–	ADC SCC, LCC, NSCLC- NOS	_	_	Stages I-IV	Naïve
Zhang et al. 2020 <sup>113</sup>	EGFR	Unicentric	248	113	135	62.23/–	ADC	117	131	Stages I-IV	Naïve
Zhang et al. 2020## <sup>68</sup>	EGFR	Unicentric	914	493	421	59.79/–	ADC	_	_	-	Naïve

Zhang et al. 2021 <sup>41</sup>	EGFR KRAS ERBB2 TP53	Unicentric	134	56	78	63.6/–	ADC, SCC, ASC	28	106	_	Not specified
Zhang et al. 2021 <sup>69</sup>	EGFR	Unicentric	420	201	219	57.43/56.5	ADC	147	273	-	Naïve Streserved.
Zhang et al. 2023 <sup>114</sup>	EGFR	Unicentric	115	_	_	-/-	NSCLC	-	_	_	Naïve 5
Zhao et al. 2019 <sup>86</sup>	EGFR	Unicentric	579	334	245	60.1/–	ADC	-	-	Stages 0-IV	Not specified wed without permission
Zhao et al. 2019 <sup>115</sup>	EGFR	Unicentric	637	368	269	59.9/–	ADC	49	588	_	Naïve So
Zhao et al. 2022 <sup>71</sup>	EGFR	Unicentric	88	39	49	64.23/–	ADC	31	57	Stages II and IV	Naïve
Zhu et al. 2022 <sup>32</sup>	EGFR	Unicentric	1092	648	442	59.59/–	ADC	-	_	Stages I-III	Naïve

Zhu et al. 2021 <sup>29</sup>	EGFR TP53	Unicentric	199	86	113	Freq./Freq.¶	ADC	94	105	Stages III-IV	Naïve
Zuo et al. 2023 <sup>87</sup>	EGFR	Multicentric	767	372	395	-/62.04	ADC	-	_	Stages I-IV Others (34 patients)	Not specified

<sup>\*</sup>Patients were excluded if treated with RT or chemotherapy, but targeted therapy is not specified.

†CT scans acquired prior surgery; no information on prior treatments.

‡Mainly adenocarcinoma cases.

§Patients did receive target treatment, but no information on the administration of other treatments (immunotherapy and/or chemotherapy) is specified.

These studies provide age data as frequencies establishing an age threshold.

\*\*Inferred that NSCLC patients were included as it is specified that 17 patients had 19Del and 20 cases had L858R mutation; EGFR mutations are very rare in SCLC.

††In this study, there are 23 patients with no information about sex.

‡‡Image acquired 3 months before PCR; no information about treatments.

§§CT images acquired within 1 month before pathological diagnosis.


¶¶ Imaging-proven progression on first- or second-generation TKIs; patients underwent chest contrast-enhanced CT at the time of confirmed progression, and the interval between CT and confirmed progression was within 3 days.

58


ADC, adenocarcinoma; ALK, anaplastic lymphoma kinase; ASC, adenosquamous carcinoma; CT, computed tomography; EGFR, epidermal growth factor receptor; ERBB2, v-erbb2 avian erythroblastic leukemia viral oncogene homolog 2; Freq., frequency; KRAS, Kirsten rat sarcoma viral oncogene homologue; LCC, large cell lung carcinoma; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; PD-L1, programmed death ligand 1; PSC, pulmonary sarcomatoid carcinoma; RT, radiotherapy; SCC, Squamous cell carcinoma; SCLC, small-cell lung cancer; TKI, tyrosine kinase inhibitor; TP53, tumor suppressor protein 53.

#### **FIGURES**


**Figure 1.** PRISMA flowchart. AI, artificial intelligence; CLAIM, Checklist for Artificial Intelligence in Medical Imaging; CT, computed tomography; MRI, magnetic resonance imaging.



**Figure 2**. Forest plots of the included studies developing radiomics models using machine learning and/or deep learning methods for the prediction of EGFR mutation status. Numbers are estimated with 95% CIs in brackets and indicated by horizontal lines. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally tag them as done in Tables 1 and 2 and in the reference list. EGFR, epidermal growth factor receptor; CI, confidence interval; DOR, diagnostic odds ration; FPR, false




**Figure 3**. Forest plots of the included studies developing combined models (radiomics + clinical data) using machine learning and/or deep learning methods for the prediction of EGFR mutation status. Numbers are estimates with 95% CIs in brackets and indicated by horizontal lines. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally tag them as done in Tables 1 and 2 and in the reference list. EGFR, epidermal growth factor receptor; CI, confidence interval; DOR, diagnostic odds ration;




FPR, false positive rate.

**Figure 4**. Forest plots of the included studies developing radiomics models using machine learning and/or deep learning methods for the prediction of **A**) ALK and **B**) KRAS mutation status. Numbers are estimates with 95% CIs in brackets and indicated by horizontal lines. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally tag them as done in Tables 1 and 2 and in the reference list. ALK, anaplastic lymphoma kinase; CI, confidence interval; DOR, diagnostic odds ration; FPR, false



positive rate; KRAS, Kirsten rat sarcoma viral oncogene homologue.


**Supplementary Figure S1.** Hierarchical sROC curves of included studies for the comparative performance of radiomics models and combined models (radiomics + clinical data) using machine learning and/or deep learning methods for the prediction of EGFR mutation status (n = 24 and n = 23 studies, respectively). EGFR, epidermal growth factor receptor.



**Supplementary Figure S2.** Hierarchical sROC curve of included studies for the performance of radiomics models for the prediction of ALK mutation status (n = 3). ALK, anaplastic lymphoma kinase.



**Supplementary Figure S3.** Hierarchical sROC curve of included studies for the performance of radiomics models for the prediction of KRAS mutation status (n = 4). KRAS, Kirsten rat sarcoma viral oncogene homologue.



### **Supplementary tables**

**Supplementary Table S1.** Search strategy applied for the qualitative analysis (systematic review).

Databases	Search strategy
MEDLINE (via Pubmed)	("radiomics"[TIAB] OR "radiomic"[TIAB] OR "texture analysis"[TIAB]) AND ("lung neoplasms"[MESH] OR "lung cancer"[TIAB] OR "NSCLC"[TIAB] or "non-small cell lung cancer"[TIAB] OR "lung adenocarcinoma"[TIAB]) AND ("mutational status" OR "mutation" OR "molecular subtype" OR "ALK"[TIAB] OR "anaplastic lymphoma kinase"[TIAB] OR "BRAF"[TIAB] OR "EGFR"[TIAB] OR "Epidermal growth factor receptor"[TIAB] OR "ERRB2"[TIAB] OR "Receptor, ErbB-2"[MESH] OR "HER2"[TIAB] OR "KRAS"[TIAB] OR "Kirsten rat sarcoma virus"[TIAB] OR "Proto Oncogene Proteins c met"[TIAB] OR "NTRK"[TIAB] OR "ROS"[TIAB] OR "c-ros"[TIAB])
COCHRANE LIBRARY	("radiomics" OR "radiomic" OR "texture analysis") AND ("lung neoplasms" OR "lung cancer" OR "NSCLC" OR "non-small cell lung cancer") AND ("mutational status" OR "mutation" OR "molecular subtype" OR "ALK" OR "anaplastic lymphoma kinase" OR "BRAF" OR "EGFR" OR "ERRB2" OR "Receptor, ErbB-2" OR "HER2" OR "KRAS" OR "Kirsten rat sarcoma virus" OR "Proto Oncogene Proteins c met" OR "NTRK" OR "ROS" OR "c-ros")
EMBASE	('radiomics':ab,ti OR 'radiomics'/exp OR 'radiomic':ab,ti OR 'texture analysis':ab,ti) AND ('lung cancer'/exp OR 'lung cancer':ab,ti OR 'NSCLC'/exp OR 'NSCLC':ab,ti OR 'non small cell lung cancer'/exp OR 'non small cell lung cancer':ab,ti OR 'lung adenocarcinoma'/exp OR 'lung adenocarcinoma':ab,ti) AND

('mutational status':ab,ti OR ('mutational' NEAR/2 'status') OR
'mutation':ab,ti OR 'mutation'/exp OR 'molecular subtype':ab,ti OR
('molecular' NEAR/2 'subtype') OR 'ALK':ab,ti OR 'ALK gene'/exp
OR 'anaplastic lymphoma kinase':ab,ti OR 'anaplastic lymphoma
kinase'/exp OR 'BRAF':ab,ti OR 'BRAF gene'/exp OR 'EGFR':ab,ti
OR 'EGFR gene'/exp OR 'Epidermal growth factor receptor':ab,ti
OR 'Epidermal growth factor receptor gene'/exp OR 'ERRB2':ab,ti
OR 'ERRB2 gene'/exp OR 'epidermal growth factor receptor 2'/exp
OR 'epidermal growth factor receptor 2':ab,ti OR 'HER2':ab,ti OR
'KRAS':ab,ti OR 'KRAS gene'/exp OR 'Kirsten rat sarcoma
virus':ab,ti OR 'Kirsten rat sarcoma virus'/exp OR 'Proto Oncogene
Proteins c met' OR 'MET':ab,ti OR 'MET gene'/exp OR
'NTRK':ab,ti OR 'NTRK gene'/exp OR 'c ros oncogene 1':ab,ti OR
'ROS1':ab,ti OR 'ROS1 gene'/exp)

# Supplementary Table S2. Quality assessment results obtained after CLAIM evaluation.

N			Score			
	Study	Reviewer 1 (A.J.P.)	Reviewer 2 (F.B.B.)	Reviewer 3 (A.P.P.)	Mean score	Cut-off
1	Chang et al. 2021 <sup>1</sup>	28	24	27	26	17
2	Chang et al. 2021 <sup>2</sup>	26	25	26	26	17
3	Dong et al. 2021 <sup>3</sup>	23	22	19	21	18
4	Dong et al. 2022 <sup>4</sup>	25	22	21	23	18
5	Feng et al. 2022 <sup>5</sup>	20	22	23	22	18.5
6	Gao et al. 2023 <sup>6</sup>	22	22	20	21	17.5
7	Huo et al. 2022 <sup>7</sup>	22	25	25	24	17.5
8	Jia et al. 2019 <sup>8</sup>	19	19	20	19	17
9	Jiang et al. 2022 <sup>9</sup>	24	23	22	23	16.5
10	Le et al. 2021 <sup>10</sup>	22	20	21	21	17.5
11	Li et al. 2018 <sup>11</sup>	25	28	22	25	19
12	Li et al. 2019 <sup>12</sup>	23	22	21	22	17
13	Li et al. 2020 <sup>13</sup>	25	23	22	23	19
14	Li et al. 2022 <sup>14</sup>	21	21	21	21	17

15	Liu et al. 2020 <sup>15</sup>	22	25	23	23	17
16	Liu et al. 2022 <sup>16</sup>	24	23	22	23	17
17	Lu et al. 2020 <sup>17</sup>	27	30	26	28	17.5
18	Lu et al. 2022 <sup>18</sup>	22	25	21	23	17.5
19	Ma et al. 2020 <sup>19</sup>	24	26	22	24	17
20	Nair et al. 2021 <sup>20</sup>	21	22	19	21	17.5
21	Ninomiya et al. 2021 <sup>21</sup>	21	22	21	21	17.5
22	Ninomiya et al. 2023 <sup>22</sup>	21	22	22	22	17
23	Rios Velazquez et al. 2017 <sup>23</sup>	19	23	20	21	18
24	Rossi et al. 2021 <sup>24</sup>	20	22	19	20	17.5
25	Song et al. 2020 <sup>25</sup>	27	28	27	27	19
26	Tu et al. 2019 <sup>26</sup>	19	21	20	20	17
27	Wang et al. 2022 <sup>27</sup>	23	26	26	25	18
28	Wang et al. 2022 <sup>28</sup>	24	22	22	23	19
29	Weng et al. 2021 <sup>29</sup>	24	25	24	24	17.5
30	Wu 2020 <sup>30</sup>	20	22	21	21	17
31	Yang 2020 <sup>31</sup>	22	23	23	23	17
32	Yang 2022 <sup>32</sup>	19	18	18	18	17
33	Zhang 2018 <sup>33</sup>	26	27	23	25	17
34	Zhang 2020 <sup>34</sup>	19	19	19	19	17
-						

35	Zhang 2020 <sup>35</sup>	22	23	23	23	17
36	Zhang 2021 <sup>36</sup>	27	26	26	26	17
37	Zhao 2022 <sup>37</sup>	23	24	23	23	19
38	Zhu 2022 <sup>38</sup>	22	22	20	21	17.5

# **Supplementary Table S3.** Studies included in the different meta-analyses conducted.

N	EGFR		ALK	KRAS
	Radiomics models	Combined models	Radiomics models	Radiomics models
1	Chang et al. 2021 <sup>1</sup>	Dong et al. 2022 <sup>4</sup>	Chang et al. 2021 <sup>2</sup>	Dong et al. 2021 <sup>3</sup>
2	Dong et al. 2021 <sup>3</sup>	Gao et al. 2023 <sup>6</sup>	Ma et al. 2020 <sup>19</sup>	Le et al. 2021 <sup>10</sup>
3	Feng et al. 2022 <sup>5</sup>	Huo et al. 2022 <sup>7</sup>	Song et al. 2020 <sup>25</sup>	Rios Velazquez et al. 2017 <sup>23</sup>
4	Gao et al. 2023 <sup>6</sup>	Jia et al. 2019 <sup>8</sup>		Wang et al. 2022 <sup>28</sup>
5	Le et al. 2021 <sup>10</sup>	Jiang et al. 2022 <sup>9</sup>		
6	Li et al. 2018 <sup>11</sup>	Li et al. 2018 <sup>11</sup>		
7	Li et al. 2019 <sup>12</sup>	Li et al. 2019 <sup>12</sup>		
8	Li et al. 2022 <sup>14</sup>	Li et al. 2020 <sup>13</sup>		

9	Liu et al. 2020 <sup>15</sup>	Liu et al. 2020 <sup>15</sup>	
10	Liu et al. 2022 <sup>16</sup>	Lu et al. 2020 <sup>17</sup>	
11	Lu et al. 2020 <sup>17</sup>	Lu et al. 2022 <sup>18</sup>	
12	Lu et al. 2022 <sup>18</sup>	Ninomiya et al. 2023 <sup>22</sup>	
13	Nair et al. 2021 <sup>20</sup>	Rios Velazquez et al. 2017 <sup>23</sup>	
14	Ninomiya et al. 2021 <sup>21</sup>	Rossi et al. 2021 <sup>24</sup>	
15	RiosVelazquez et al. 2017 <sup>23</sup>	Tu et al. 2019 <sup>26</sup>	
16	Tu et al. 2019 <sup>26</sup>	Wang et al. 2022 <sup>27</sup>	
17	Wang et al. 2022 <sup>27</sup>	Weng et al. 2021 <sup>29</sup>	
18	Weng et al. 2021 <sup>29</sup>	Wu 2020 <sup>30</sup>	
19	Yang 2020 <sup>31</sup>	Yang 2022 <sup>32</sup>	
20	Zhang 2020 <sup>34</sup>	Zhang 2018 <sup>33</sup>	

21	Zhang 2020 <sup>35</sup>	Zhang 2020 <sup>35</sup>	
22	Zhang 2021 <sup>36</sup>	Zhang 2021 <sup>36</sup>	
23	Zhao 2022 <sup>37</sup>	Zhu 2022 <sup>38</sup>	
24	Zhu 2022 <sup>38</sup>		

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homologue.

**Supplementary Table S4.** Type of models (radiomic model/deep learning or combined [radiomic features + clinical variables]) developed in the studies for EGFR prediction and the radiomics/clinical features included. EGFR, epidermal growth factor receptor.

Study	Models	Radiomic features	Clinical variables
		ShortRunLowGreyLevelEmphasis_AllDirection_offset1_SDH	N/A
		Percentile85	
		OneVoxelVolume	
		Flatness	
		ShortRunEmphasis_AllDirection_offset_SD	
Chang et al. 2021 <sup>1</sup>	Radiomic	HaralickCorrelation_AllDirection_offset4_SD	
		Zone Percentage	
		GLCM_Entropy_AllDirection_offset7_SD	
		Correlation_AllDirection_offset7_SD CT_GLCMEntropy_AllDirection_offset1_SD	
		HaralickCorrelation_angle135_offset7	
		LongRunHighGreyLevelEmphasis_angleO_offset 1	
		ShortRunLowGreyLevelEmphasis_AllDirection_offset7_SD	

		HaralickCorrelation_AllDirection_offset1_SD	
		SurfaceVolumeRatio	
Dong et al. 2021 <sup>3</sup>	Deep learning	Not specified	N/A
		wavelet-HLL_GLCM_MaximumProbability	Smoking status
		wavelet-LLL_GLCM_MaximumProbability	Histological type
		original_GLCM_SumEntropy)	
		log-sigma-1-0-mm-3D_GLCM_MaximumProbability	
Dong et al. 2022 <sup>4</sup>	Combined	wavelet-LHL_firstorder_Kurtosis	
		wavelet-LLL_firstorder_Skewness	
		log-sigma-2-0-mm-3D_firstorder_Kurtosis	
		original_shape_Sphericity	
		wavelet-LHL_GLSZM_LargeAreaHighG	
		Skewness.7_firstorder_wavelet-LHL SmallAreaHighGrayLevelEmphasis.7_GLSZM_wavelet-LHL	
_		HighGrayLevelZoneEmphasis.12_GLSZM_wavelet-HHH 90Percentile_firstorder_original	
Feng et al. 2022 <sup>5</sup>	Radiomic	Variance.4_firstorder_square	
		Range.4_firstorder_square	

		GrayLevelVariance.26_GLSZM_wavelet-LHH	
		JointAverage.11_GLCM_wavelet-HLH	
		MeanAbsolute Deviation.4_firstorder_square RobustMeanAbsoluteDeviation.4_firstorder_square	
		GrayLevelNonUniformity.32_GLSZM_wavelet-LLH   GrayLevelNonUniformity.1_girlm_original	
		GrayLevelNonUniformity.4_girlm_logarithm GrayLevelNonUniformity.16_girlm_squareroot	
		HighGrayLevelRunEmphasis.5_girlm_squareroot	
		GrayLevelNonUniformityNormalized.21_GLSZM_wavelet-LLH LowGrayLevelRunEmphasis girlm_original LowGrayLevelRunEmphasis.5_girlm_squareroot GrayLevel Variance.32_GLSZM_wavelet-LLH	
		Minimum.4_firstorder_square SmallArealowGrayLevelEmphasis.11_GLSZM_wavelet-HLH SmallArealowGrayLevelEmphasis.12_GLSZM_wavelet-HHH	
		Mean.12_firstorder_wavelet-HHH SmallArealowGrayLevelEmphasis.9_GLSZM_wavelet-HLL	
		Imc2.12 GLCM wavelet-HHH	N/A
		ADC	
		original_firstorder_Kurtosis	
Gao et al. 2023 <sup>6</sup>	Radiomic	original_firstorder_Median	CEA
Gao et al. 2023°	Combined	original_firstorder_Skewness	Sex (male)
		log-sigma-1-0-mm-3D_firstorder_Energy	Nodule type (sub-

		log-sigma-4-0-mm-3D_GLDM_DependenceVariance	solidity)
		wavelet-LHL_GLRLM_LongRunLowGrayLevelEmphasis	
		wavelet-HLL_firstorder_Energy	
			Age
Huo et al. 2022 <sup>7</sup> *	Combined	137 features (not specified)	Sex (female)
Tiuo et al. 2022	Combined	137 reatures (not specified)	Non-smokers
			Clinical stage (I-II)
Jia et al. 2019 <sup>8</sup>	Combined	94 features (not specified)	Sex
31a Ct al. 2017	Combined	74 readules (not specifica)	Smoking history
		Skewness	
		Minimum	
Jiang et al. 2022 <sup>9</sup>	Combined	Kurtosis	
Jiang et al. 2022	Combined	Variance	
		Minimum	Age
		10th percentile	Sex

		SumSquare	Smoking
		SizeZoneNonUniformity	Tumor
		HighGrayLevelZoneEmphasis	Family history
		ZoneVariance	
		LargeDependence HighGrayLevelEmphasis	
		LargeDependenceHighGrayLevel Emphasis	
		DependenceEntropy	
		wavelet-LLLfirstorderEnergy	
	Radiomic	wavelet-LHHGLSZMGrayLevelNonUniformityNormalized	
		wavelet-HHLGLDMSmallDependenceLowGratLevelEmphasis	N/A
Le et al. 2021 <sup>10</sup>		wavelet-HLHGLCM_MCC	
		wavelet-HLHGLSZMSmallAreaLowGrayLevelEmphasis	
		wavelet-HHHGLCMjointEnergy	
		wavelet-HHHGLRLMGrayLevelNonUniformityNormalized	
	Radiomic	220 5 4 7 7 15 15	Sex
Li et al. 2018 <sup>11</sup>	Combined	338 features (not specified)	Smoking status

		CT_GGS_Gray Span	Age
	Radiomic	CT_GGC_Gray Mean	Sex
Li et al. 2019 <sup>12</sup>	Combined		Smoking status
	Combined		Clinical stage
			Lesion location
			Sex
Li et al. 2020 <sup>13</sup>	Combined	12 features (not specified)	Age
			Smoking status
Li et al. 2022 <sup>14</sup>	Radiomic	3 features (not specified)	-
		RADIOMIC MODEL:	
		wavelet-HLH_GLDM_DependenceVariance	
Liu et al. 2020 <sup>15</sup>	Radiomic	wavelet-LHL_GLDM_LargeDependenceLowGrayLevelEmphasis	
Liu et al. 2020	Combined	logarithm_GLCM_InverseVariance	
		square_GLDM_DependenceVariance	
		wavelet-HLH_GLDM_LargeDependenceHighGrayLevelEmphasis	

wavelet-HHH_GLCM_Id	
log-sigma-0-5-mm-3D_GLSZM_ZoneEntropy	
square_GLCM_Correlation	Age
original_GLCM_ClusterShade	Sex
wavelet-LHH_GLDM_LargeDependenceHighGrayLevelEmphasis	Smoking history
COMBINED MODEL:	
wavelet-HLH_GLDM_DependenceVariance	
custom_PatientSex	
logarithm_GLCM_InverseVariance	
square_GLCM_Correlation	
wavelet-HLL_firstorder_Kurtosis	
wavelet-LHL_GLRLM_LongRunLowGrayLevelEmphasis	
wavelet-HLL_firstorder_Median	
original_GLSZM_SizeZoneNonUniformityNormalized	
exponential_firstorder_Skewness	

		wavelet-LLH_GLCM_ClusterShade	
		Mean absolute deviation	
		60 Percentile area	
		Convex	
		Correlation	
		Dissimilarity	
		5-1 Homogeneity 2	
		10-4 Homogeneity 2	
Liu et al. 2022 <sup>16</sup>	Radiomic	-333-7 Information measure corr 1	
		8-1 Information measure corr 1	
		9-7 Information measure corr 1	
		2-4 Inverse diff norm	
		6-4 Inverse variance	
		8-4 Inverse variance	
		8-1 Max Probability	
		12-7 Max Probability	

		-333 Run length nonuniformity	
Lu et al. 2020 <sup>17</sup>	Radiomic Combined	original_GLSZM_SmallAreaHighGrayLevelEmphasis original_GLSZM_SmallAreaLowGrayLevelEmphasis original_GLDM_LowGrayLevelEmphasis log-sigma-1-0-mm-3D_GLCM_Cluster Prominence log-sigma-3-0-mm-3D_GLDM_DependenceNonUniformityNormalized wavelet- LLL_GLCM_InverseVariance wavelet-LLH_GLCM_Imc2 wavelet-HLL_firstorder_Mean wavelet-HLL_GLSZM_LowGrayLevelZoneEmphasis wavelet-HLL_GLDM_SmallDependenceHighGrayLevelEmphasis wavelet-HLH_GLSZM_SizeZoneNonUniformityNormalized wavelet-HHH_firstorder_Skewness wavelet-HHH_GLSZM_Size Zone Non Uniformity Normalized	Sex Smoking status Pathohistological subtype Vascular infiltration status
Lu et al. 2022 <sup>18</sup>	Radiomic Combined	1269 features (not specified)	Age Sex Smoking status Stage of disease

			Serum level of tumor
			markers (CEA,
			CYFRA 21-1, SCC,
			Pro-GRP)
Nair et al. 2021 <sup>20†</sup>	Radiomic	NGTDM_600_Complexity  Glrl_Saggital_30_ShortRunEmphasis  Glrl_Saggital_30_ShortRunHighGrayLevelEmphasis  Glrl_Saggital_120_ShortRunHighGrayLevelEmphasis  Glrl_Coronal_120_ShortRunHighGrayLevelEmphasis  Glrl_Coronal_30_ShortRunEmphasis  Glrl_Saggital_120_ShortRunEmphasis  Glrl_Axial_30_ShortRunEmphasis  Glrl_Axial_30_ShortRunEmphasis  Glrl_Coronal_120_ShortRunEmphasis  FirstOrder_HistogramBin2	_
Ninomiya et al. 2021 <sup>21</sup>	Radiomic	BN MODEL: b0_GLCM_Energy_45,	
		b1/b0_GLSZM_ZSN_104	

		b1_GLCM_SumAverage_122	_
		b0_GLRLM_Lrlge_97)	
		OI MODEL:	
		GLRLM_ ShortRunLowGrayLevelEmphasis	
		GLSZM_ LowGrayLevelZoneEmphasis	
		GLSZM_ShortZoneLowGrayEmphasis	
		WD MODEL:	
		GLSZM_ LowGrayLevelZoneEmphasis _LL	
		GLSZM_SmallAreaLowGrayLevelEmphasis	
Ninomiya et al.	G II I	GLSZM_LargeAreaEmphasis	Sex
2023 <sup>22</sup>	Combined	Hist.RootMeanSquared	Smoking status
		GLDM_DependenceVariance	
Rios Velazquez et al.	Radiomic	imaging.Wavelet_LHH_GLCM_invDiffmomnor	
2017 <sup>23</sup>	Combined	imaging.LoG_sigma_3_mm_3D_GLSZM_highIntensityLarteAreaEmp	

	im	aging.Wavelet_LLL_GLCM_clusProm		
	im	aging.GLCM_maxProb		
	im	aging.Wavelet_LLL_stats_energy	imaging.Wavelet_HLL_stats_var	
		aging.LoG_sigma_3_mm_3D_GLSZM_largeArea	Emphasis imaging.Wavelet_LLH_stats_range	Stage
		aging.Wavelet_LHH_GLCM_clusProm aging.Wavelet_LLL_GLSZM_highIntensityLarteA	ureaEmp	Sex
	im	aging.Wavelet_HLH_GLSZM_lowIntensitySmall	·	Smoking status
	im	aging.Stats_median	imaging.Wavelet_HHL_GLCM_maxProb	Age
	im	aging.LoG_sigma_3_mm_3D_GLCM_clusProm in	maging.Shape_spherDisprop	Race
	im	aging.Stats_kurtosis		
	im	aging.Wavelet_HHH_GLCM_correl1		
	im	aging.LoG_sigma_3_mm_3D_rlgl_grayLevelNonu	ıniformity	
	Fir	rst order_90 Percentile		
	Fir	est order_Entropy		Sex
Rossi et al. 2021 <sup>24</sup> Co	ombined Fir	rst order_Maximum		Smoking status
	Fir	est order_Median		
	Fir	est order_Robust mean absolute deviation		

First order_Root mean squared	
First order_Skewness	
First order_Uniformity	
GLCM_Correlation	
GLCM_Difference average	
GLCM_Difference entropy	
GLCM_InverseDifference	
GLCM_ InverseDifferenceMoment	
GLCM_ InverseDifferenceMomentNormalized	
GLCM_ InverseDifferenceNormalized	
GLCM_ InformationalMeasureCorrelation1	
GLCM_ InformationalMeasureCorrelation2	
GLCM_InverseVariance	
GLCM_JointEnergy	
GLCM_JointEntropy	
GLCM_MaximalCorrelationCoefficient	

GLCM_MaximumProbability	
GLCM_SumEntropy	
GLDM_DependenceEntropy	
GLDM_DependenceNonUniformity	
GLDM_Dependence NonUniformityNormalized	
GLDM_DependenceVariance	
GLDM_GrayLevelNonUniformity	
GLDM_LargeDependenceEmphasis	
GLDM_SmallDependenceEmphasis	
GLRLM_GrayLevelNonUniformity	
GLRLM_GrayLevelNonUniformityNormalized	
GLRLM_RunEntropy	
GLRLM_RunPercentage	
GLRLM_ShortRunEmphasis	
GLSZM_GrayLevelNonUniformity	
GLSZM_GrayLevelNonUniformityNormalized	

		GLSZM_SizeZoneNonUniformityNormalized	
		GLSZM_SmallAreaEmphasis	
		GLSZM_ZoneEntropy	
		GLSZM_ZoneVariance	
		NGTDM_Coarseness	
	Radiomic	X0_GLRLM_ RunLengthNon-Uniformity	Maximum diameter
Tu et al. 2019 <sup>26</sup>	Combined	X4_H_median	Location
	Combined	X0_GLCM_homogeneity1	Sex
			Age
			Sex
	Radiomic		Tumor staging
Wang et al. 2022 <sup>27</sup>	Combined <sup>‡</sup>	Not specified	Number
	Combined.		Age Sex Tumor staging
			Past recurrence
			Medication status

Weng et al. 2021 <sup>29</sup>	Combined	SmallAreaEmphasis  LongRunHigh GreyLevelEmphasis_angle0_offset4  ClusterProminence_All Direction_offset7_SD  InverseDifference Moment_All Direction_offset4_SD  LowGreyLevel Run Emphasis_All Direction_offset4_SD  LongRunLowGrey Level Emphasis_All Direction_offset7_SDCorrelation_angle0_offset7  std Deviation  GLCM Energy_All Direction_offset4_SD	Smoking status  Spiculation  Air bronchogram  CEA  SCCA
Wu 2020 <sup>30</sup>	Combined	Not specified	Smoking status Histological subtype
Yang 2020 <sup>31</sup>	Radiomic	Not specified	-
Yang 2022 <sup>32</sup>	Radiomic Combined	Nonwavelet-LHH_NGTDM_Strength  wavelet-LHH_GLDM_DependenceEntropy  wavelet-LLL_GLSZM_LargeAreaLowGrayLevelEmphasis  wavelet-LLL_firstorder_Minimum	Sex Emphysema Interstitial lung disease

		wavelet-LLH_NGTDM_Contrast	
		wavelet-LHH_NGTDM_Strength	
		log-sigma-1-5-mm-3D_firstorder_Kurtosis	
		wavelet-LHL_GLCM_ClusterShade	
		wavelet-LHH_NGTDM_Strength	
		wavelet-LLL_GLSZM_LargeAreaLowGrayLevelEmphasis	
		wavelet-LLH_firstorder_Mean	
		original_NGTDM_Contrast	
		original_firstorder_Kurtosis	
		log-sigma-1-5-mm-3D_firstorder_Kurtosis	
		wavelet-LLL_NGTDM_Contrast	
		original_GLCM_MaximumProbability	
		wavelet-LLL_GLSZM_LargeAreaLowGrayLevelEmphasis	
		IIF.range	Histological subtype
Zhang 2018 <sup>33</sup>	Combined	IIF.Skewness	Sex
		W <sub>LLH</sub> F.IF.mean_absulute_eviation	Smoking status

		W <sub>LHH</sub> F.IF.median	
		W <sub>LLH</sub> F.IF.mean	
		W <sub>LLH</sub> F.GLCM.variance	
		GLRLM_ HighGrayLevelRunEmphasis	
		GLSZM_ HighGrayLevelZoneEmphasis	
71 202034	D 1: :	GLDM_DependenceVariance	
Zhang 2020 <sup>34</sup>	Radiomic	GLSZM_ GreyLevelNon UniformityNormalized	_
		GLSZM_ZoneEntropy	
			Sex
71 202035	Radiomic	704.0 ( ) ( )	Histopathological
Zhang 2020 <sup>35</sup>	Combined	784 features (not specified)	Subtype
			Age
		fo_Skewness	Smoking history
202136	Radiomic	exp_GLRLM_ShortRunEmphasis	Bubble-like lucency
Zhang 2021 <sup>36</sup>	Combined	exp_GLRLM_ShortRunHighGrayLevelEmphasis	Pleural attachment
		exp_GLDM_SmallDependenceEmphasis	Pleural retraction

		grad_GLDM_DependenceEntropy	
		LLH_fo_90P	
		LLH_GLCM_SumEntropy	
		LLL-fo_kurtosis	
		LLL-GLCM_ClusterProminence	
		LLL_GLSZM_GrayLevelNonUniformityNormalized	
		LLL_GLSZM_GrayLevelVariance	
		LLL_GLSZM_ZoneEntropy	
		CT_Shape_Sphericity	
		CT_GLRLM_ShortRunEmphasis	
Zhao 2022 <sup>37§</sup>	Radiomic	CT_GLRLM_ShortRunHighGreyLevelEmphasis	-
		CT_NGLDM_Busyness	
		CT_Glzlm_ShortZoneEmphasis	
	D - 4''	log_sigma_1.0_mm_3D_GLRLM_RunVariance	Sex
Zhu 2022 <sup>38</sup>	Radiomic	wavelet_LLH_firstorder_RootMeanSquared	Age
	Combined	log-sigma-2-0-mm-3D_GLCM_ClusterShade	Emphysema

wavelet_HHH_firstorder_Mean	Pathological subtype

\*Combined model also included 14 CT features: location (peripheral), tumor size ≥3cm, subsolid density, spiculation, lobulation, air bronchogram, air space, necrosis, calcification (presence), vascular convergence sign, pleural retraction sign, pleural effusion, lymphatic metastasis and multiple pulmonary metastasis.

†Top 10 selected features. The maximum number of texture features included was determined by maximizing cross-validated accuracy. This value was not the same for each binary group or each machine learning model.

‡Note that this model includes radiomic features + deep features and clinical variables.

§Model 1.

BN, Betti numbers; CEA, carcinoembryonic antigen; CYFRA 21-1, fragment of cytokeratin sub-unit 19; GLCM, gray-level co-occurrence matrix; GLDM, gray-level dependence matrix; GLRLM, gray-level run-length matrix; GLSZM, gray-level size zone matrix; NGTDM, neighbouring gray tone difference matrix; OI, original image; Pro-GRP, pro-gastrin-releasing peptide; SCC, squamous cell carcinoma antigen; WD, wavelet decomposition.

**Supplementary Table S5.** Type of models (radiomic model or combined [radiomic features + clinical variables]) developed in the studies for ALK prediction and the radiomics/clinical features included. ALK, anaplastic lymphoma kinase.

Study	Models	Radiomic features	Clinical variables
		CT_uniformity	
		CT_LongRunEmphasis_AllDirection_offset4_SD	
		CT_HaraEntropy	
		CT_GLCMEnergy_angle135_offset7	
		CT_LongRunHighGreyLevelEmphasis_angle45_offset1	
Chang et al. 2021 <sup>2</sup>	Radiomic	CT_LongRunLowGreyLevelEmphasis_AllDirection_offset7_SD	
Chang et al. 2021	Radioniic	CT_Correlation_AllDirection_offset4_SD	
		CT_Percentile70	
		CT_HaralickCorreltion_AllDirection_offset4_SD	
		CT_LongRunLowGreyLevelEmphasis_AllDirection_offset4_SD	-
		CT_LongRunEmphasis_angle135_offset4	
		CT_LongRunHighGreyLevelEmphasis_angle90_offset4	

	CT_LongRunLowGreyLevelEmphasis_AllDirection_offset1_SD	
	CT_HaralickCorreltion_AllDirection_offset7_SD	
	CT_ShortRunEmphasis_AllDirection_offset1_SD	
	CT_LongRunHighGreyLevelEmphasis_angle0_offset1	
	CT_GLCMEntropy_angle90_offset1	
	CT_Percentile30	
	CT_LongRunEmphasis_angle90_offset4	
	CT_LongRunEmphasis_AllDirection_offset1_SD	
	PRE-CONTRAST MODEL:	
	wavelet-LLL_GLCM_DifferenceVariance	
D. II.	wavelet-LLH_firstorder_Median	
Radiomic	wavelet-LLH_NGTDM_Busyness	_
	wavelet-LHL_GLSZM_LargeAreaLowGrayLevelEmphasis	_
	wavelet-HHH_GLSZM_LargeAreaLowGrayLevelEmphasis	
	wavelet-LHL_firstorder_Energy	
	Radiomic	CT_HaralickCorreltion_AllDirection_offset7_SD  CT_ShortRunEmphasis_AllDirection_offset1_SD  CT_LongRunHighGreyLevelEmphasis_angle0_offset1  CT_GLCMEntropy_angle90_offset1  CT_Percentile30  CT_LongRunEmphasis_angle90_offset4  CT_LongRunEmphasis_AllDirection_offset1_SD  PRE-CONTRAST MODEL:  wavelet-LLL_GLCM_DifferenceVariance  wavelet-LLH_firstorder_Median  wavelet-LLH_NGTDM_Busyness  wavelet-LHL_GLSZM_LargeAreaLowGrayLevelEmphasis  wavelet-HHH_GLSZM_LargeAreaLowGrayLevelEmphasis

wavelet-HHL_firstorder_90Percentile	
wavelet-HHL_GLCM_JointEntropy	
wavelet-HHL_firstorder_Uniformity	
wavelet-HHL_firstorder_RobustMeanAbsoluteDeviation	
wavelet-LHH_GLDM_LargeDependenceLowGrayLevelEmphasis	
wavelet-HLH_firstorder_Median	
wavelet-LHL_GLDM_LargeDependenceLowGrayLevelEmphasis	
wavelet-HHL_GLCM_InverseDifference	
wavelet-HHL_firstorder_InterquartileRange	
wavelet-HHL_GLCM_MaximumProbabiblity	
wavelet-HHH_GLSZM_SmallAreaLowGrayLevelEmphasis	
wavelet-HHL_firstorder_Mean	
wavelet-HLL_GLCM_ClusterShade	
wavelet-HHL_GLSZM_SmallAreaLowGrayLevelEmphasis	
wavelet-LHH_GLCM_ MaximalCorrelationCoefficient	
wavelet-LLL_GLSZM_SizeZoneNonUniformityNormalized	

wavelet-LLL\_GLSZM\_SmallAreaEmphasis wavelet-HHL\_GLCM\_ InverseDifferenceNormalized **POST-CONTRAST MODEL:** wavelet-LHH\_GLDM\_SmallDependenceHighGrayLevelEmphasis wavelet\_HHL\_GLSZM\_GrayLevelNonUniformity wavelet-LLH\_firstorder\_Mean  $wavelet-LLH\_GLSZM\_HighGrayLevelZoneEmphas is$ wavelet-LLH\_GLSZM\_SmallAreaHighGrayLevelEmphasis wavelet-LLH\_GLSZM\_SmallAreaLowGrayLevelEmphasis wavelet-HHH\_GLCM\_MaximumProbability  $wavelet-LLL\_GLDM\_LargeDependenceLowGrayLevelEmphas is$ wavelet-HLL\_GLDM\_DependenceVariance wavelet-HHH\_firstorder\_Mean wavelet-HHH\_GLDM\_LowGrayLevelEmphasis wavelet-LLH\_firstorder\_90Percentile

		wavelet-HHL_GLDM_DependenceVariance	
		wavelet-HHH_GLCM_MaximalCorrelationCoefficient	
		wavelet-HHH_NGTDM_Contrast	
		wavelet-original_GLCM_InverseVariance	
		wavelet-LLH_firstorder_Range	
		wavelet-HHL_GLCM_MaximalCorrelationCoefficient	
		wavelet-HLL_GLSZM_GrayLevelNonUniformityNormalized	
		RADIOMIC MODEL:	
	D. II.	Original_Firstorder_90Percentile	
		Original_Firstorder_Entropy	
Song et al. 2020 <sup>25</sup>	Radiomic Combined	Original_Firstorder_Maximum	
	Combined	Wavelet-LHH_Firstorder_10Percentile	
		Wavelet-HLL_Firstorder_Median	Age
		Wavelet-HHH_Firstorder_Mean	Sex
		LoG-sigma-1-0-mm-3D_Firstorder_Median	Smoking history

LoG-sigma-1-0-mm-3D_Firstorder_RootMeanSquared	Smoking index
LoG-sigma-1-0-mm-3D_Firstorder_Minimum	Clinical stage Distal metastasis
LoG-sigma-2-0-mm-3D_Firstorder_10Percentile	Pathological
LoG-sigma-3-0-mm-3D_Firstorder_90Percentile	invasiveness of the
LoG-sigma-5-0-mm-3D_Firstorder_Skewness	tumor
Original_ GLCM _ClusterShade	
Wavelet-LHH_ GLCM _Correlation	
Wavelet-LHL_ GLCM _InverseDifferenceNormalized	
Wavelet-HHH_ GLCM _InformationalMeasureofCorrelation1	
LoG-sigma-1-0-mm-3D_GLCM _Autocorrelation	
LoG-sigma-2-0-mm-3D_GLCM _InverseVariance	
Original_GLSZM_ SmallAreaHighGrayLevelEmphasis	
Wavelet-HHH_ GLSZM _ SmallAreaHighGrayLevelEmphasis	
Wavelet-HLL_ GLSZM _ZoneEntropy	
Wavelet-HLH_ GLSZM _ZoneEntropy	
LoG-sigma-2-0-mm-3D_GLSZM _ZoneEntropy	

LoG-sigma-3-0-mm-3D\_GLSZM \_ SmallAreaEmphasis LoG-sigma-3-0-mm-3D\_GLSZM \_ Size-ZoneNonUniformityNormalized LoG-sigma-5-0-mm-3D GLSZM GrayLevelNonUniformityNormalized Wavelet-LHH\_GLDM\_ LargeDependenceHighGrayLevelEmphasis LoG-sigma-1-0-mm-3D\_GLDM \_ HighGrayLevelEmphasis LoG-sigma-3-0-mm-3D\_GLRLM\_RunPercentage LoG-sigma-4-0-mm-3D\_GLRLM \_ LongRunLowGrayLevelEmphasis **COMBINED MODEL:** Current smoker Stage I Male Local lymphadenopathy Pericardial effusion Left Lower Lobe lesion No cavity in the lesion

Lobulated margin No pleural retraction sign No local lymphadenopathy Wavelet-HHL\_Firstorder\_Kurtosis Wavelet-HLL\_Firstorder\_Median Wavelet-LHH\_Firstorder\_Skewness Wavelet-LLL\_Firstorder\_Minimum Wavelet-HLH\_Firstorder\_Median LoG-sigma-1-0-mm-3D\_Firstorder\_Minimum LoG-sigma-2-0-mm-3D\_Firstorder\_Minimum Wavelet-LLL GLCM ClusterShade Wavelet-LLH\_GLCM InformationalMeasureofCorrelation2 Wavelet-HLH\_GLCM \_InformationalMeasureofCorrelation2  $Wavelet-HLH\_GLCM\_Informational Measure of Correlation 1$  $LoG\text{-}sigma\text{-}1\text{-}0\text{-}mm\text{-}3D\_GLCM\_Informational Measure of Correlation 1}$  $LoG\text{-}sigma\text{-}3\text{-}0\text{-}mm\text{-}3D\_GLCM\_InformationalMeasure} of Correlation 2$ 

LoG-sigma-5-0-mm-3D_GLCM_InformationalMeasureofCorrelation2	
Original_Shape_MajorAxisLength	
Wavelet-HLH_GLSZM_SizeZoneNon-Uniformity	
LoG-sigma-4-0-mm-3D_GLSZM_GrayLevelNonUniformityNormalized	
Wavelet-HLH_GLDM_ LargeDependenceHigh GrayLevelEmphasis	
Wavelet-HHH_GLDM_ LargeDependenceHigh GrayLevelEmphasis	
Original_GLRLM_ HighGrayLevelRunEmphasis	

GLCM, gray-level co-occurrence matrix; GLDM, gray-level dependence matrix; GLRLM, gray-level run-length matrix; GLSZM, gray-level size zone matrix; NGTDM, neighbouring gray tone difference matrix.

**Supplementary Table S6.** Type of models (radiomic model or combined [radiomic features + clinical variables]) developed in the studies for KRAS prediction and the radiomics/clinical features included. KRAS, Kirsten rat sarcoma viral oncogene homologue.

Study	Models	Radiomic features	Clinical variables
Dong et al. 2021 <sup>3</sup>	Radiomic	Not specified	_
		wavelet-LLHGLSZMLargeAreaEmphasis	
	Radiomic	wavelet-LLLGLDMDependenceEntropy	
		wavelet-LHHGLDMLargeDependenceLowGrayLevelEmphasis	
Le et al. 2021 <sup>10</sup>		ori-firstorderkurtosis	
Le et al. 2021		wavelet-HLHGLCMInverseVariance	_
		wavelet-HLLGLSZMSmallAreaHighGrayLevelEmphasis	
		wavelet-LHHGLCMld	
		wavelet-HHLGLCMDifferenceEntropy	

		wavelet-LLLGLSZMGrayLevelNonUniformityNormalized	
		wavelet-HHHGLCMDifferenceAverage	
		wavelet-HHHGLDMDependenceEntropy	
		imaging.LoG_sigma_3_mm_3D_GLSZM_highIntensityLarteAreaEmp	
		imaging.Wavelet_LHH_GLCM_clusProm imaging.Wavelet_LHH_GLCM_energy	
		imaging.Wavelet_LLL_stats_energy imaging.Wavelet_LLL_stats_median	
		imaging.LoG_sigma_3_mm_3D_GLSZM_largeAreaEmphasis	
		imaging.Wavelet_HHH_GLSZM_lowIntensitySmallAreaEmp	
		imaging.Wavelet_HHH_GLCM_correl1 imaging.LoG_sigma_3_mm_3D_GLCM_clusProm	
D' Wil	•	imaging.Wavelet_LLL_GLSZM_highIntensityLarteAreaEmp imaging.Wavelet_HHL_stats_energy	
RiosVelazquez et al.		imaging.Wavelet_HLL_stats_var imaging.Wavelet_HLH_GLSZM_lowIntensitySmallAreaEmp	Stage
2017 <sup>23</sup>		imaging.Wavelet_LHH_rlgl_GrayLevelNonuniformity	g.
		imaging.LoG_sigma_3_mm_3D_GLSZM_lowIntensitySmallAreaEmp imaging.GLCM_clusShade	Sex
		imaging.Wavelet_LHH_GLCM_invDiffmomnor imaging.Wavelet_HLL_stats_min	Smoking status
		imaging.Wavelet_LLL_rlgl_longRunHighGrayLevEmpha imaging.Wavelet_LLH_stats_mean	A ~ a
			Age
			Race
W	D - 4''	CT_square_GLSZM_SizeZoneNonUniformityNormalized	
Wang et al. 2022 <sup>28</sup>	Radiomic	CT_wavelet-LHH_GLDM_DependenceNonUniformityNormalized	_

CT_wavelet-HHL_firstorder_Skewness
CT_wavelet-HHL_GLDM_DependenceNonUniformityNormalized

GLCM, gray-level co-occurrence matrix; GLDM, gray-level dependence matrix; GLRLM, gray-level run-length matrix; GLSZM, gray-level size zone matrix.

**Supplementary Table S7.** Results of the meta-regression analyzing the effects of age, type of segmentation (manual/semi-automatic/automatic), type of model (radiomics/combined [radiomic features + clinical data) and artificial intelligence methodology (machine learning/deep learning).

AGE						
Fixed-effects coefficients						
	Estimate	SE	Z	<i>p</i> -value	CI 95%	
tsens.(Intercept)	4.488	2.181	2.058	0.040	[0.214, 8.762]	
tsens.AGE	-0.052	0.035	-1.483	0.138	[-0.121, 0.017]	
tfpr.(Intercept)	-0.156	2.288	-0.068	0.946	[-4.640, 4.328]	
tfpr.AGE	-0.012	0.037	-0.318	0.750	[-0.084, 0.061]	
Variance components: between-studies Std. Dev and correlation matrix						
	SD tsens tfr				tfpr	

	SD	tsens	tfpr
tsens	0.395	-	0.819
tfpr	0.431	0.819	-

# TYPE OF SEGMENTATION

Fixed-effects coefficients

	Estimate	SE	Z	<i>p</i> -value	CI 95%
tsens.(Intercept)	1.217	0.127	9.599	0.000	[0.968, 1.465]
tsens.SegmentationSemiautomatic	-0.086	0.241	-0.356	0.722	[-0.558, 0.387]

tsens.SegmentationUnknown	0.347	0.708	0.491	0.624	[-1.040, 1.734]
tfpr.(Intercept)	-0.984	0.133	-7.426	0.000	[-1.244, -0.725]
tfpr.SegmentationSemiautomatic	0.272	0.254	1.067	0.286	[-0.227, 0.770]
tfpr.SegmentationUnknown	0.397	0.697	0.569	0.569	[-0.970, 1.763]

Variance components: between-studies Std. Dev and correlation matrix

	SD	tsens	tfpr
tsens	0.465	-	0.827
tfpr	0.511	0.827	-

### **CONTRAST**

# Fixed-effects coefficients

	Estimate	SE	Z	<i>p</i> -value	CI 95%
tsens.(Intercept)	1.244	0.608	2.045	0.041	[0.052, 2.437]
tsens.Contrastcontrast-enhanced	0.151	0.650	0.232	0.817	[-1.124, 1.425]
tsens.Contrastnon-contrast CT	-0.096	0.620	-0.156	0.876	[-1.312, 1.119]
tfpr.(Intercept)	-0.619	0.638	-0.970	0.332	[-1.870, 0.632]
tfpr.Contrastcontrast-enhanced	-0.509	0.683	-0.745	0.456	[-1.848, 0.829]
tfpr.Contrastnon-contrast CT	-0.309	0.650	-0.476	0.634	[-1.584, 0.965]

Variance components: between-studies Std. Dev and correlation matrix

	SD	tsens	tfpr
tsens	0.468	-	0.889
tfpr	0.511	0.889	-

### TYPE OF MODEL

Fixed-effects coefficients

	Estimate	SE	Z	<i>p</i> -value	CI 95%
tsens.(Intercept)	1.281	0.133	9.603	0.000	[1.020, 1.543]
tsens.Modelrad	-0.193	0.197	-0.980	0.327	[-0.579, 0.193]
tfpr.(Intercept)	-0.939	0.146	-6.413	0.000	[-1.226, -0.652]
tfpr.Modelrad	0.006	0.222	0.026	0.979	[-0.429, 0.441]

Variance components: between-studies Std. Dev and correlation matrix

	SD	tsens	tfpr
tsens	0.434	-	0.828
tfpr	0.524	0.828	-

# **AI METHODOLOGY**

Fixed-effects coefficients

	Estimate	SE	Z	<i>p</i> -value	CI 95%
tsens.(Intercept)	1.215	0.232	5.2240	0.000	[0.761, 1.670]
tsens.TypeML	-0.022	0.257	-0.087	0.930	[-0.526, 0.481]

tfpr.(Intercept)	-0.898	0.257	-3.489	0.000	[-1.403, 0.394]
tfpr.TypeML	-0.052	0.285	-0.184	0.854	[-0.610, 0.505]

Variance components: between-studies Std. Dev and correlation matrix

	SD	tsens	tfpr
tsens	0.442	-	0.795
tfpr	0.520	0.795	-

AI, artifical intelligence; CI, confidence interval; ML, machine learning; rad, model including only radiomic features; SE, standard error; SD, Standard deviation; z, standard score in a gaussian distribution; tsens, logarithmic transformation of sensitivity; tfpr, logarithmic transformation of false positive rate.

#### **REFERENCES**

- 1 Chang C, Zhou S, Yu H et al. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma. *Eur Radiol*. 2021; 31(8): 6259-6268.
- 2 Chang C, Sun X, Wang G et al. A machine learning model based on PET/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma. *Front Oncol.* 2021; 11: 603882.
- Dong Y, Hou L, Yang W et al. Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images. *Quant Imaging Med Surg.* 2021; 11(6): 2354-2375.
- Dong Y, Jiang Z, Li C et al. Development and validation of novel radiomics-based nomograms for the prediction of EGFR mutations and Ki-67 proliferation index in non-small cell lung cancer. *Quant Imaging Med Surg.* 2022; 12(5): 2658-2671.
- Feng Y, Song F, Zhang P et al. Prediction of EGFR mutation status in non-small cell lung cancer based on ensemble learning. *Front Pharmacol*. 2022; 13: 897597.
- Gao J, Niu R, Shi Y et al. The predictive value of [(18)F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma. *EJNMMI Res.* 2023; 13(1): 26.
- Huo JW, Luo TY, Diao L et al. Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma. *Front Oncol.* 2022; 12: 846589.
- 8 Jia TY, Xiong JF, Li XY et al. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. *Eur Radiol*. 2019; 29(9): 4742-4750.
- 9 Jiang M, Yang P, Li J et al. Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and

- efficacy of first-line targeted therapy in lung adenocarcinoma. *Front Oncol.* 2022; 12: 985284.
- 10 Le NQK, Kha QH, Nguyen VH et al. Machine learning-based radiomics signatures for EGFR and KRAS mutations prediction in non-small-cell lung cancer. *Int J Mol Sci.* 2021; 22(17).
- Li XY, Xiong JF, Jia TY et al. Detection of epithelial growth factor receptor (EGFR) mutations on CT images of patients with lung adenocarcinoma using radiomics and/or multi-level residual convolutionary neural networks. *J Thorac Dis.* 2018; 10(12): 6624-6635.
- Li X, Yin G, Zhang Y et al. Predictive power of a radiomic signature based on (18)F-FDG PET/CT images for EGFR mutational status in NSCLC. *Front Oncol.* 2019; 9: 1062.
- Li S, Luo T, Ding C et al. Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learning. *Med Phys*. 2020; 47(8): 3458-3466.
- Li S, Li Y, Zhao M et al. Combination of (18)F-fluorodeoxyglucose PET/CT radiomics and clinical features for predicting epidermal growth factor receptor mutations in lung adenocarcinoma. *Korean J Radiol*. 2022; 23(9): 921-930.
- Liu G, Xu Z, Ge Y et al. 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma. *Transl Lung Cancer Res.* 2020; 9(4): 1212-1224.
- Liu Y, Zhou J, Wu J et al. Development and validation of machine learning models to predict epidermal growth factor receptor mutation in non-small cell lung cancer: a multi-center retrospective radiomics study. *Cancer Control*. 2022; 29: 10732748221092926.
- Lu X, Li M, Zhang H et al. A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma. *Phys Med Biol.* 2020; 65(5): 055012.

- 18 Lu J, Ji X, Wang L et al. Machine learning-based radiomics for prediction of epidermal growth factor receptor mutations in lung adenocarcinoma. *Dis Markers*. 2022; 2022: 2056837.
- Ma DN, Gao XY, Dan YB et al. Evaluating solid lung adenocarcinoma anaplastic lymphoma kinase gene rearrangement using noninvasive radiomics biomarkers. *Onco Targets Ther*. 2020; 13: 6927-6935.
- Nair JKR, Saeed UA, McDougall CC et al. Radiogenomic models using machine learning techniques to predict EGFR mutations in non-small cell lung cancer. *Can Assoc Radiol J.* 2021; 72(1): 109-119.
- Ninomiya K, Arimura H, Chan WY et al. Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers. *PLoS One*. 2021; 16(1): e0244354.
- Ninomiya K, Arimura H, Tanaka K et al. Three-dimensional topological radiogenomics of epidermal growth factor receptor Del19 and L858R mutation subtypes on computed tomography images of lung cancer patients. *Comput Methods Programs Biomed*. 2023; 236: 107544.
- Rios Velazquez E, Parmar C, Liu Y et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. *Cancer Res.* 2017; 77(14): 3922-3930.
- Rossi G, Barabino E, Fedeli A et al. Radiomic detection of EGFR mutations in NSCLC. *Cancer Res.* 2021; 81(3): 724-731.
- Song L, Zhu Z, Mao L et al. Clinical, conventional ct and radiomic feature-based machine learning models for predicting ALK rearrangement status in lung adenocarcinoma patients. *Front Oncol.* 2020; 10: 369.
- Tu W, Sun G, Fan L et al. Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. *Lung Cancer*. 2019; 132: 28-35.
- Wang C, Ma J, Shao J et al. Predicting EGFR and PD-L1 status in NSCLC patients using multitask ai system based on CT images. *Front Immunol.* 2022; 13: 813072.

- Wang J, Lv X, Huang W et al. Establishment and optimization of radiomics algorithms for prediction of KRAS gene mutation by integration of NSCLC gene mutation mutual exclusion information. *Front Pharmacol*. 2022; 13: 862581.
- Weng Q, Hui J, Wang H et al. Radiomic feature-based nomogram: a novel technique to predict EGFR-activating mutations for EGFR tyrosin kinase inhibitor therapy. *Front Oncol.* 2021; 11: 590937.
- Wu S, Shen G, Mao J et al. CT radiomics in predicting EGFR mutation in non-small cell lung cancer: a single institutional study. *Front Oncol.* 2020; 10: 542957.
- Yang C, Chen W, Gong G et al. Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma. *Transl Cancer Res.* 2020; 9(11): 6683-6690.
- Yang X, Liu M, Ren Y et al. Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics nomogram analysis. *Eur Radiol*. 2022; 32(4): 2693-2703.
- Zhang L, Chen B, Liu X et al. Quantitative biomarkers for prediction of epidermal growth factor receptor mutation in non-small cell lung cancer. *Transl Oncol.* 2018; 11(1): 94-101.
- Zhang M, Bao Y, Rui W et al. Performance of (18)F-FDG PET/CT radiomics for predicting EGFR mutation status in patients with non-small cell lung cancer. Front Oncol. 2020; 10: 568857.
- Zhang B, Qi S, Pan X et al. Deep CNN model using CT radiomics feature mapping recognizes EGFR gene mutation status of lung adenocarcinoma. *Front Oncol.* 2020; 10: 598721.
- Zhang G, Cao Y, Zhang J et al. Predicting EGFR mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature. *Am J Cancer Res.* 2021; 11(2): 546-560.

- Zhao HY, Su YX, Zhang LH et al. Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma. *Neoplasma*. 2022; 69(1): 233-241.
- Zhu H, Song Y, Huang Z et al. Accurate prediction of epidermal growth factor receptor mutation status in early-stage lung adenocarcinoma, using radiomics and clinical features. *Asia Pac J Clin Oncol*. 2022; 18(6): 586-594.